Skip to content
Get App

Psilocybin Summit Nov12 EN

Canadian veterans and advocates testify before a parliamentary-style panel on psilocybin therapy, sharing personal healing experiences and calling for regulated access.

Key Takeaways

  • Patients who have exhausted conventional treatments report meaningful benefit from psilocybin-assisted therapy and want legal, regulated access.
  • Current Canadian exemption processes are slow and bureaucratic, causing harm to patients awaiting approval.
  • Rigorous research and responsible clinical pathways should accompany any expansion of access.
  • Canada could build domestic psilocybin production capacity and learn from international models such as Australia's.

What the video covers

  • Veteran Josh Venois shares how psilocybin therapy helped him after SSRIs, antipsychotics, and CBT failed to relieve his trauma.
  • Speakers argue psilocybin should be available beyond veterans and first responders to all Canadians facing mental health struggles.
  • Gordon Hurley, a medically released special operations veteran, describes six years of psilocybin use and psychedelic-assisted therapy in Mexico.
  • Speakers reference neuroplasticity research suggesting psilocybin temporarily alters brain communication, enabling new thought patterns.
  • The case of Thomas Hardle, the first Canadian granted a legal psilocybin exemption, is highlighted as an example of bureaucratic delays despite approval.
  • Testimony describes patients with stage 4 cancer finding relief through psilocybin-assisted therapy and facing loss of access afterward.
  • Speakers call for rigorous research, clinical trials, and monitored implementation programs within Canadian healthcare systems.
  • Public policy arguments cite addictions and mental health crises costing Canada over $100 billion annually.
  • Australia's authorized prescriber scheme (2023) is cited as a model allowing psychiatrists to prescribe psilocybin.
  • Speakers advocate for a Canadian-owned, Canadian-produced psilocybin supply to ensure sovereignty rather than reliance on international partners.

Answers

Questions about this video

What personal experience does Josh Venois describe?

Venois says he tried SSRIs, antipsychotics, and cognitive behavioral therapy without success before finding psilocybin therapy. He says the medicine helped him connect emotionally with lessons he had learned intellectually in therapy.

Why does Gordon Hurley say psilocybin has been important for him?

Hurley, a medically released special operations veteran, says he has used psilocybin since 2020 and credits it with helping him stay well through a turbulent transition. He also paid for psychedelic-assisted psychotherapy in Mexico and followed it with cognitive processing therapy.

What problem do speakers raise about the regulatory process?

Speakers say the system is slow and inconsistent, citing Thomas Hardle, who was granted an exemption but had to wait for renewal while his cancer progressed. Others describe receiving lengthy refusal letters despite clinicians believing they would benefit.

Full Transcript — Download SRT & Markdown

00:33
Speaker A
Okay. So, we'll get started this afternoon. Um, as Corey said, each speaker will be allowed 5 minutes of speaking time. I'll try and give a one minute warning and uh then it will be followed by questions and answers. And
00:45
Speaker A
our first speaker this afternoon is Josh Venois. as a veteran, but I'm also here today to speak about my personal experience as a human being using psilocybin to heal from traumatic experiences in my life.
01:13
Speaker A
As veterans, we've partnered with some of the most bright minds and dedicated minds in this country and internationally. The knowledge, expertise, and infrastructure already exists in Canada for us to work alongside our allies advancing this very important discussion. This this
01:26
Speaker A
discussion is about warrior healing, recovery, and hopefully retention. But this just isn't about veterans or first responders. This is about all Canadians.
01:35
Speaker A
And as a veteran, we're here to help breach that door so that others may get the opportunity to benefit from safe, regulated access to psilocybin in its natural form.
01:44
Speaker A
While the past can provide us with valuable lessons, the future is written by those who make the most of the now.
01:50
Speaker A
These moments matter. What we do with them matters. That's why I'm here today. I believe people deserve the opportunity to explore safe clinical evidence informed pathways to whole mushroom preparations.
02:02
Speaker A
Today, I'm grateful and proud we're discussing psilocybin at a national level. We have Thomas Bill from Corey Tucker and his colleagues seeking to establish pathways for regulated access. That alone demonstrates just how far we've come.
02:17
Speaker A
My experience with psilocybin, well, it wasn't easy. It was a battle. It took me a long time to find the right medicine. I tried SSRIs. I tried anticychotics. I did all the work. I did cognitive behavioral therapy. It took me
02:34
Speaker A
many, many years of finding different modalities that just weren't effective. I was getting weaker. I wasn't really going to make it much longer. Life was getting dark. The walls were closing in.
02:47
Speaker A
That's when I finally found psilocybin therapy. I spoke with clinicians, researchers, other colleagues, and eventually I decided to do that work.
02:57
Speaker A
The work deeply mattered. Cognitive behav cognitive behavioral therapy gave me tools, language, and perspective. But knowing something intellectually and actually feeling it are two very different things. Knowing that you should be able to feel good but not being able to access it is deeply
03:12
Speaker A
troubling for the soul. For me, the medicine was not replacement for the work and it never will be. It helped me connect with myself and connect with the work that I had already done. The preparation, professional support, and
03:24
Speaker A
integration of these experiences deserve to be central to any responsible clinical pathway moving forward.
03:29
Speaker A
There's significant scientific interest in how psilocybin affects the brain and its neural networks. Research tells us psilocybin promotes neuroplasticity, the brain's ability to form, strengthen, and reorganize neural connections.
03:40
Speaker A
Essentially, our brains can become accustomed to certain patterns of thinking and responding to the world around us. Some of these patterns, particularly those shaped by trauma, can be incredibly difficult to change.
03:50
Speaker A
Psilocybin temporarily alters how different regions of the brain communicate, creating an opportunity to develop new perspectives and healthier thought patterns. And for me personally, that's what made this experience so profound. I could finally begin to feel some of the things I had learned in
04:03
Speaker A
therapy. I was able to connect with those lessons emotionally rather than simply intellectually understanding them. And I began carrying those tools forward into my everyday life. The potential relationship between psilocybin and neurot neuroplasticity and lasting therapeutic change is still
04:17
Speaker A
being studied, but it's it's a very incredibly important area of research. And allowing this to be regulated will allow these brilliant minds to study this at scale and for fractions of the cost. As veterans, we want to show the
04:29
Speaker A
rest of Canada what resilience looks like. That recovery is something tangible and possible. There is life beyond what happened to you. You are not defined by your trauma. We are more than our jobs. and more than our ranks and
04:39
Speaker A
titles, the money we make or how we look. We all deserve to have a human experience.
04:45
Speaker A
I struggled to get where I am today. As I mentioned, it was a battle and perhaps one of the hardest ones I've ever fought. But my experience has shown me that meaningful change is possible. I still do the work because we are human.
04:56
Speaker A
We must remember to show ourselves the same empathy and understanding and grace that we would extend to others. Through my own experience, I found a pathway that has made a profound difference in my life. And I believe that we have a
05:06
Speaker A
responsibility to investigate how these therapies might help others. Not just armed service members, not just veterans, first responders, but all Canadians from all walks of life who are struggling.
05:16
Speaker A
[sighs] [snorts] To anyone who feels that they are running out of options, I want you to know that we see you. We recognize you. We see your struggles and you are not alone. Walk with us on this journey.
05:27
Speaker A
While Canadian Armed Forces members serve to continue and defend the sovereignty of nations around the world, we have a responsibility here at home to advance conversations about healing, recovery, and better access to mental health care. We have lived these
05:39
Speaker A
experiences. We have done the work and many of us have found meaningful benefits through this emerging therapy.
05:44
Speaker A
Our experiences deserve to be heard. Our researchers deserve to the opportunity to investigate these treatments and Canadians deserve informed conversations about the possibilities that lie lie ahead. We have this life here and now.
05:57
Speaker A
So, let's make the most of it. Thank you. Thank you, Josh. Next, we're going to go to Gordon Hurley.
06:10
Speaker A
Good afternoon. Can you hear me? Can you guys give me a thumbs up that you can hear me? All right. Sweet.
06:20
Speaker A
All right, guys. Thank you so much for having me this afternoon. My name is Gordon Hurley. I served 15 years in the Canadian Armed Forces, half in special operations. I was medically released in 2021.
06:33
Speaker A
I'll start with the part that matters the most in this room. I use psilocybin.
06:38
Speaker A
I have since 2020. I started during my release from the military, which was one of the most turbulent stretches of my life. Anyone here who has been through a medical release or sat with somebody going through a medical release or a
06:51
Speaker A
large transition knows what it does to a person. You lose the job, the identity, the people, the structure all at once.
06:59
Speaker A
And that is on top of what you're already carrying, right? The war, the PTSD, the injuries, which is why they're releasing you in the first place.
07:09
Speaker A
Psilocybin has helped im sorry psilocybin has helped me immensely through it all six years. Six years later this isn't an experiment guys. This is how a part of that I this is how I am able to stay well. I say that out loud because a lot
07:26
Speaker A
of the people this bill is about can't say it. They're doing it quietly without a physician without any dose anybody measured without anybody know it is happening at all. In 2023, I went to Mexico for psychedelic assisted psychotherapy. I paid for that myself,
07:43
Speaker A
too. I came home and did cognitive processing therapy on the back of it. And that broke open the deepest part of me.
07:50
Speaker A
I want to talk about Thomas, Mr. Hardle. When this became new, my new mission in life, getting veterans access to this, Thomas Hardle was one of the first people that came I came across. I watched him speak on a webinar. He
08:04
Speaker A
actually gave it from his hospital bed. I came off that call very confused, confused by why this man had to go through to get something his own country had already said yes to and I was very confused about how badly it was handled
08:19
Speaker A
and the fact that nobody could simply give him the care on time. Thomas was the first Canadian granted a legal exemption to use psilocybin. Then the same system that said yes made him wait the full renewal while his cancer kept
08:32
Speaker A
moving. And that's what we're trying to fix here. Not access in principle, access in time. Now the report. Three years ago this month, the Senate subcommittee on Veterans Affairs tabled a report called the time is now. It made
08:48
Speaker A
one recommendation. One, that the government of Canada immediately launch and fund a large-scale research program into psychedelic assisted psychotherapy through Veterans Affairs and National Defense with Health Canada and Canadian Institutes of Health Research.
09:03
Speaker A
The government answered on 10 October 2024. There are not many operative words, so I'll read them to you. The government takes note of this recommendation and will continue to actively monitor the research. Take note. Actively monitor. The report was
09:18
Speaker A
called the time is now. The answer was that the time is actually later. I'll be fair. Veterans Affairs told the Senate it was running an updated internal review on clinical evidence. That was two years ago. I don't know where that
09:31
Speaker A
is, where the review is, or if anybody ever finished it, and I would love to have someone in this room give me an answer on that. That'd be that'd be great. Here's what active monitoring looks like from where I'm standing.
09:42
Speaker A
Veterans are dosing themselves in their own homes, on their own guesswork, no clinician anywhere near it, because the alternative is nothing. The ones with money get on planes. The ones who don't do it alone in their basement. And not
09:56
Speaker A
one data point from any of this reaches a researcher, which means in three years of monitoring, we have learned nothing from them. Meanwhile, one regular force veteran dies by suicide every 9 days.
10:06
Speaker A
And that's not my number. That's the Parliament's own number from the standing committee on Veterans Affairs drawn from Veteran Affairs Canada's own veteran suicide morality mortality study. Three years of monitoring. You can do the arithmetic yourself. I do not
10:20
Speaker A
want to wait. And I'll be quick about this part. Last November, I appeared right here in this room on the Standing Committee on Veterans Affairs and its study on suicide prevention and tabled the Veterans Accelerated Access and Research Program, a pilot pathway to
10:34
Speaker A
regulated access. Since then, I've put it in front of several government officials. I make a documentary series on advanced force operations because policy follows the public and the public follows a story. The second film is paired with a study at the University of
10:47
Speaker A
Ottawa research ethics boards approved and we've been recruiting since August. Already producing follow-up data. One veteran out of his own pocket with a university partner is generating the evidence the Senate asked the government for 3 years ago. If I can do that, the
11:02
Speaker A
government can do that. Which brings me to C286. Thomas's bill is narrow and sensible. It moves psilocybin and psilocin out of restricted schedule restricted drug schedule and into the controlled drug framework that already exists. It requires priority review for miss for
11:18
Speaker A
submissions involving them. It does not go around Health Canada. It makes the path faster and more predictable. I'd rather be a patient than a criminal. So would every other veteran I know who is doing this on their own right now. Pass
11:31
Speaker A
C286, then do the thing the Senate said they would do three years ago and fund the research with veterans in it. Thomas waited. He ran out of time. The people I work with are still waiting.
11:43
Speaker A
Thank you. Thank you, Gordon. And now we'll open it up for questions and answers.
11:52
Speaker A
First off, um gentlemen from on behalf of a very grateful parliament and a nation, thank you for your public service. Um it is individuals like you two that uh ensure that we have the freedoms uh that we're blessed with here
12:06
Speaker A
in Canada. So, thank you very much for that and thank you for your testimony on what psilocybin treatments has meant to you. I've um I've yet to meet a Canadian that believes that a citizen can't access the medicine that their their
12:23
Speaker A
physician is prescribing. And I was wondering if you could um kind of um thinking back to some of your conversations with other veterans maybe um introducing them to the idea of psilocybin. Um what is um what is usually the response when you you talk
12:41
Speaker A
to some of your former colleagues or your your fellow veterans about counseling? That question is to me, Mr. Tucker.
12:51
Speaker A
Sure. We we'll start with you then we'll go to Josh. All right. Sorry, Josh. Um, well, they're always very curious. They're always very very very skeptical of the system that's put them in this position with the over uh reliance and
13:06
Speaker A
overprescribing of prescription medications that has destroyed the veteran landscape and has put people in such an imbalance that uh when I talk to the ones the ones that are suicidal I have to explain it to them that hey if
13:22
Speaker A
you're on five different prescription drugs and you're not taking them right and you're drinking you're not even you right now man. So they are so freaked out by the western uh method of uh medicine, namely prescription drugs, and
13:36
Speaker A
that's caused like uh sanctuary trauma and all sorts of weird stuff that puts the veteran now even more adversarial against the government. So they're very very interested.
13:46
Speaker A
They love the fact that it's uh a safer option than what's out there right now.
13:53
Speaker A
Um and the the proof is in the pudding. It's not, this isn't like made up.
13:58
Speaker A
There's so much research and data behind this that when they finally get a peer-to-peer, a veteran new veteran conversation about like, dude, you don't have to do this, i.e. suicide or whatever else is going on in your life
14:10
Speaker A
and you can give them an option that's safe and effective and backed by research they're they're going to take that, Gordon.
14:16
Speaker A
Right. And I I've had some of those conversations, but Josh, if you think back to some of your conversations with your fellow veterans, anything to share?
14:24
Speaker A
Yes, Corey. Of course, uh, a lot of what I would have to say would reiterate what Gourd was just mentioning. There's a lot of skepticism. We we see that, uh, we see a lot of institutional betrayal.
14:33
Speaker A
These guys were overmedicated for years, uh, given pharmaceutical pills that just ruined their lives basically. Um, recently a friend of mine passed away.
14:43
Speaker A
Uh, he took his own life in September. And um when some of our other our friends were there in the home, they took out two very large bags of uh ziplockc bags full of pills that were conflicting medications. These were pill
14:58
Speaker A
these were pills that were given to him uh in doses that were high enough to kill him. Um and he was left without peer support. No one was checking in on him. These are toxic medications. The fact that we're giving these to our to
15:10
Speaker A
our men and women just blows my mind. Uh it's it's still it's pretty heartbreaking because as Gourd mentioned like we are our friends are dropping like flies and we're doing everything that we can uh to sustain them as as
15:21
Speaker A
best we can but we need the correct medicine. We need the right medicine and the skepticism is broken down by the trust relationship. That's why I'm here.
15:30
Speaker A
That's why Gourd's here and we have all of these amazing people here with us today and yourself, Cory. The more that we build this trust relationship with Canadians and show them this is effective. Look at what this can do for
15:39
Speaker A
us. look at what it can do for you and that'll open up the conversation that will break down the stigma.
15:44
Speaker A
And you talk about what it could do for you. One of the more um aha moments I've had for the last four years is it's not just our veterans that have benefited from counseling with psilocybin. It's some of our G7 allies um our NATO allies
15:59
Speaker A
that um to the south um they've put in hundreds of millions of dollars into research and support for psilocybin with their veterans. And as a country, we've we've it's a we pale in comparison, correct? The research dollars.
16:14
Speaker A
Correct. Canada's lagging behind. Uh we are seeing all of our partnered allied nations moving forward with this research. It would be amazing for Canada to catch up because these data sets are out there. If we're combining our collective efforts, this is going to get
16:28
Speaker A
a lot further down the line and get into the the lives of people that it needs to help.
16:33
Speaker A
Thank you so much for your testimony and your answers. Uh, we're going to switch up the panel and Helen, who do we have next? Can I Can I see Gourd? Can I wave to him? See you, Gordo. Love you, buddy.
16:45
Speaker A
See you guys. Love you, buddy. Next up, we have Amberly Guaca. Guac. Sit right.
17:05
Speaker A
Awesome. An everyone can you hear me? You're ready to go. Good. Okay. Anin everyone and thank you for the opportunity to be a part of this conversation. My name is Amberly Quaciz and I'm an Oji way qui from Brunswick
17:39
Speaker A
House First Nation where I currently serve as deputy chief. I also have a background in law, education, social work and I've spent much of my career working in First Nation communities with youth through land-based programming and cultural revitalization.
17:54
Speaker A
Um, but today I'm not speaking on behalf of my First Nation. I'm here to speak about my own experience with psilocybin and to talk about the mental health addictions crisis and that's affecting our communities and about the work we're
18:05
Speaker A
doing to explore psilocybin assisted therapy as an alternative pathway to healing. Um, like a lot of people, I'm a workaholic and I've struggled with burnout and finding balance in everyday life. I've been on my own healing journey for quite some time,
18:20
Speaker A
reconnecting with culture, working in community, and spending time on the land. And to be honest, there's nothing more healing and satisfying than rekindling those connections. However, earlier this year, I learned about psilocybin assisted therapy. And um I became curious and decided to explore it
18:37
Speaker A
on my own. Uh what really stayed with me after this experience was how much my perspective shifted both during the experience and after. The anxieties that I regular regularly carried seemed to quiet and I was able to take a step back
18:53
Speaker A
and look at my life from a much broader perspective. And in some ways that was a familiar feeling to me.
19:00
Speaker A
I've taken part in important ceremonies such as 4-day fasts as well as helping at sundances and taking part in sweats.
19:08
Speaker A
And I've experienced how powerful it can be to truly disconnect and reflect. Going into these ceremonies, I am actively seeking clarity and purpose, and I often come away with a shift in perspective. Now, I'm not saying that the experiences are the same, but
19:23
Speaker A
recognizing those parallels in my own healing journey really caught my attention. All to say that my experience with psilocybin did not solve everything, nor did I expect it to, but it showed me its potential and made me curious about what could be possible
19:35
Speaker A
with the therapeutic support. In my own community, we're seeing a mental health and addictions crisis that we're really trying to get ahead of. Too many of our people are struggling and the supports available aren't always accessible or meeting our needs. So,
19:49
Speaker A
when I recently brought up uh PAT to a psychotherapist that's been working in my community for 7 years, he instantly lit up. He was in and he really wanted to get involved. Um he shared some inspiring stories about people he knew
20:04
Speaker A
who managed to turn their lives around after using psilocybin. sometimes without therapeutic support. He also told me he's heard people say that it saved their lives. Um, this conversation was a turning point for me. He knows my community, understands the challenges
20:19
Speaker A
we're facing, and he sees real potential for something like this back home, and leadership agrees. So, we're looking forward to bringing this conversation to our tribal council in a few weeks to explore a pilot program that could serve
20:30
Speaker A
multiple First Nations in the north. I truly believe in my people's culture and ceremonies and I think that PAT could complement our traditional ways of healing. I'd love to see First Nations involved in research and pilot programs from the very beginning
20:44
Speaker A
um with guidance from elders and traditional knowledge keepers. I've recently become involved in the effort to establish a national pilot program for the first nations psilocybin assisted therapy and a lot of work in relationship building has already gone
20:59
Speaker A
into this initiative and I'm excited to be a part of something that could really help change people's lives. I understand that uh PAT is still being studied and that there are important questions about safety effectiveness and regulation but
21:12
Speaker A
the reality is that the people are struggling right now and need more options. With the right funding, partnerships, and safeguards, I believe we can make these treatments more accessible to the people who really need them. And I know it may not be the
21:23
Speaker A
answer for everyone, but for those who've tried everything available to them and are running out of options, I think we owe it to them to make this accessible to them.
21:32
Speaker A
Um, because for some it could make all the difference. Much for your time. Thank you, Amberly. Next, we'll have Otis Jasper.
21:44
Speaker A
Thank you. Good day. I thank you for for the opportunity to be here. I raise my hands to member Tucker for for creating this opportunity. Uh I'm located in the Fraser Valley in in British Columbia. I come from uh the community of Salei. uh
22:11
Speaker A
in my experience I'm a part of a group called sacred circle and we've been working uh in this space for the last five years as part of our own research our own process our own pathway most of us uh are former leadership or current
22:25
Speaker A
leadership in our communities um uh three of us are also now RCC's uh as part of this path that we've been walking uh we had applied to uh SUOP in 2022 to run a a a program with psilocybin in our communities. Uh we
22:46
Speaker A
weren't successful in that. However, we we revisited it with it and we were successful in getting it with a ket with ketamine. So, we ran a two and a half year program in our communities. Uh just some of the learnings from that
23:00
Speaker A
which would be applied with with psilocybin as well for our communities similar to other populations. uh our health-seeking behavior is is poor. Uh in order to access and go into uh different facilities and buildings outside of our communities can be a
23:18
Speaker A
challenge for for many of our our members. So our program brought it into the community and our reach uh was with the community and essentially we had about 60 to 80 individuals who came through our program. uh we had doctors,
23:33
Speaker A
we had nurses, we had therapists uh throughout the program. So they were the ones prescribing and making sure it was a right fit for our members. Uh and so most of our participants were from word of mouth. So their brothers, their
23:50
Speaker A
sisters, their aunts, their uncles, their children were the ones being referred to us and they'd go meet with our doctors and go through the process to determine if it was the right fit for them. And so I I feel like that is
24:02
Speaker A
something that often in in when when programs come out uh our indigenous communities are not always at the forefront in consideration. So the call out here would also to be finding alternative ways to for our our individuals, our communities to access
24:21
Speaker A
this these medicines. I think in my experience with working with participants and family members, the ones who who have the poor health-seeking behavior, what I've found is following going through this process with with with uh ketamine or psilocybin,
24:43
Speaker A
um the willingness and the openness to access further services and to make a better use of those services. I see psilocybin as a multiplier uh in making the whole system that much more better for individuals.
24:58
Speaker A
In my own view, I I feel that a a complex community approach is what's necessary to to provide the the best services for for our members. Uh a quick example, we had a couple of our participants who had
25:18
Speaker A
accessed uh their own medicines uh not through any any channel just just on their own.
25:27
Speaker A
Uh and that's a part of the risk is is individuals accessing it sometimes in perfect settings and other times not so perfect settings and it can create more harm than than good. And so the push for this approach, be it a pilot, be
25:44
Speaker A
something for our communities, I think is would be very much uh of value. And I I approached today and I continue to approach this with hope. And in my experience with being exposed to these medicines, being exposed to psilocybin,
25:58
Speaker A
and seeing and witnessing individuals and families go through this process with psilocybin, hope they've been through, in some cases, treatment. They've been through so many different pathways ready to give up and you can see it in them and you can feel it and you can see
26:19
Speaker A
what they do afterwards. That hope is what drives me in this path and again just thanking you for this opportunity to be here. Bahigh.
26:30
Speaker A
Thank you Otis and I'll turn it over to you for questions and answers. Uh thank you so much for being here today and sharing some of your your knowledge. Um, it's the indigenous knowledge that is important um, in our
26:42
Speaker A
history and in what we do. And that's why with Thomas' bill and our Sils Huben Summit, it's important to have your voices heard. Um, it is a voice that goes back hundreds of years of history with psychedelics. And it is through
26:59
Speaker A
some of the conversations I've had with with uh roadmen and medicine men from the indigenous culture that really opened my eyes about how plant medicines can work within western uh societies.
27:14
Speaker A
And my question I guess would be um that I would hear from both of you is what what are the what are the barriers that um indigenous population have that uh others might not know when they're looking for help with addictions and
27:34
Speaker A
mental health. Um, I would say one that comes to mind for me in my community, I guess, is that a lot of our ceremonies require days of sobriety prior to entering ceremony. And that can be a bit of a barrier or a
27:53
Speaker A
deterrent because a lot of our funding and a lot of the programs that we try to offer are um traditional cultural ceremony. And um I'm excited for Jasper to share a bit. He he was speaking about how they've designed new pathways to
28:10
Speaker A
help um overcome those kind of barriers which is very inspiring because we're in the very early stages and trying to think of how to overcome those. So have to tell you what to say. Uh I I think the first thing that comes to mind
28:27
Speaker A
uh which is it's probably not unique to our communities but stigma and a lot of that of of trying to one just even with mental health but let alone accessing something that has the history uh where it's viewed as a drug versus a medicine.
28:43
Speaker A
And so part of the work that we've been doing is connecting with folks in in Mexico and South America uh to to learn from them and have a better understanding of how they work with it within their communities. And so I think
28:58
Speaker A
uh stigma being one of the big factors. Uh, I'm actually doing my my PhD right now and and part of the work I'm doing is to create space and understanding within our communities with leadership and others to to to help work through the
29:13
Speaker A
stigma, help work through different pieces around what what is psilocybin and and what's its history.
29:23
Speaker A
And um if you could um maybe um unpack a little bit more about uh the population you think um that would benefit um maybe some if you have a um a story that you are comfortable sharing of a a friend or
29:41
Speaker A
family some of the challenges that that that are typical in in some of the cultures in Canada that others don't h unfortun or fortunately for them doesn't have to suffer with. What's that life like?
29:56
Speaker A
So, uh, an individual comes to mind, uh, over over years. Uh, we've connected, uh, sometimes 3 or 4 in the morning.
30:06
Speaker A
He's on my front front step. And so, he's one who's been through multiple treatment centers. Uh, he's been through multiple processes of trying to to walk a a sober life. uh he went through our program and and he has
30:26
Speaker A
he's now at a year and a half I believe of sobriety. He's back in school. He's regularly seeing a counselor. Uh to see his smile, to see the transition that he's made, it's not without struggle continuing, but he he now accesses
30:41
Speaker A
various services and supports uh in finding his way. And that's he's the prime example of when I thought of hope uh and seeing his transformation and his transition and impact that has on the rest of his family and and in the
30:57
Speaker A
community uh I think is is is who I I think of in my mind for motivation to to carry on.
31:08
Speaker A
Um yeah, I guess I could just share that I actually have a number of friends who've also um like they're now sober for two years, four years or and you know, it's a major milestone and it's very but it uh they also expressed that
31:21
Speaker A
it doesn't necessarily get easier and that when we started talking about psilocybin assisted therapy, they were talking about how it would be nice to have some sort of maintenance and something to help along the way and to keep um yeah to stay in control. So,
31:36
Speaker A
and we we've heard this from other patients and doctors. It's not a magic pill. It's not a silver bullet that fixes all. It's the patient needs to want to have that change and do the hard work, the integration sessions
31:49
Speaker A
afterwards. Um, but I'd like to also thank uh to both of you individually too that of um you're willing to do the work. you you've talked about how you would like to have more research in silven done within your um uh
32:04
Speaker A
communities. I I think that uh highlighting some of the areas where we as a country has denied indigenous funding for research um to our peril where additional research and subset um sets of our our population will unear um
32:22
Speaker A
unique aspects of that that subset that would benefit differently from psilocybin maybe and how it's presented maybe on more of on on the spiritual side. I I the importance of um spirituality indigenous populations is important and I've sat through different
32:40
Speaker A
ceremonies where it is incorporated that that uh that special sauce it seems and some of the indigenous use of psilocybin is is the the reconnecting spiritually um to the creator and I just uh applaud all that have been uh willing to help us
32:57
Speaker A
out and thank you for being here today. Thank you. Thank you. Next up we have Erica Dick and Nicholas and N sorry sorry and Nicholas Pope.
33:14
Speaker A
Erica first. Uh thank you everyone. Can you hear me? Okay. Thank you. Uh my name is Erica Dick. I'm a historian and professor Canada research chair at the University of Saskatchewan and I'm coming to you from Copenhagen today. Um
33:34
Speaker A
I I've been studying the history of psychedelics for over 25 years and uh I want to thank my the panelists here and the previous speakers. It's really important to hear hear voices from the community. It's something that I've
33:47
Speaker A
tried to do in my research um and I'll speak a little bit about here today.
33:52
Speaker A
Canada has an opportunity here to reinvest in the kind of psychedelic research that uh Thomas's bill suggests.
34:00
Speaker A
Canada was one of the first places on on the international scene in the 1950s, coining the word psychedelic when it came to compassionate access to psychedelic substances uh specifically for clinical categories. the 1950s used different language, but we're really
34:19
Speaker A
seeing a return to some of the concerns around treatment resistance categories. We see this in depression, we see this in substance use, um, and we also see it in trauma- based injuries or trauma- based experiences. And I think what I
34:31
Speaker A
what I've tried to track historically is where both Canada has taken the lead and where we have an opportunity to learn from that past. Um, for example, we've seen the impact of the stigma. Um Otis spoke eloquently about this when it comes specifically to
34:48
Speaker A
recognizing this within communities. We also recognize it when it comes to the concerns about the stigma that is carried forward from past psychedelic abuses. And I think we have an opportunity to do better this time to to have our our minds open a little bit
35:03
Speaker A
more widely this time around. I'm the reason I mentioned I'm I'm here in Copenhagen is that there are there's international pressure um perhaps even an opportunity for Canada to step up and take a leadership role. I'm here as part
35:16
Speaker A
of a training group that is doing an intensive workshop for therapists as there's a growing demand that is global to meet the needs of patients um and families and communities that are seeking these kinds of alternative therapies where we've seen um a kind of
35:31
Speaker A
roadblocks and challenges in meeting some of the current demands for a ballooning uh mental health crisis, mental health and addictions crisis.
35:39
Speaker A
It's interesting sitting here after spending a week with uh European regulators as well as students and clinicians and we're dealing with some of the same problems and yet we have some I think specific and unique opportunities in Canada to piece these
35:52
Speaker A
things together. We recognize that um other jurisdictions, Australia being one example, New Zealand is another one, are drawing and looking to Canada for support both legally and as well in terms of supplies. And in terms of some of the community-led research that we
36:07
Speaker A
have over the years and over the decades really demonstrated capacity to to show leadership to show creativity in these areas and it's it's exciting perhaps finally as a historian to see us maybe turning the corner here and moving
36:21
Speaker A
towards a brighter future. And I mean that not because I think that uh psychedelics are the magic pill um despite sometimes the way we call them uh that are going to solve everything, but I think it brings together people in
36:34
Speaker A
interesting ways. And again, I'm boyed and and uh inspired by the words of the previous panelists to see where communities can take the lead in integrating uh these substances not as the substance but as part of a pathway
36:48
Speaker A
towards a different way of thinking about mental health, addiction, and even suicide in some areas. And I I raised that in part because I think there's been some work with Justice Canada as well looking at prison populations and
37:00
Speaker A
looking at ways to bring down some of the recidivism as well as some of the um challenging circumstances faced by um the sort of the comorbid conditions existing within the present population.
37:13
Speaker A
Um I I just want to say one last thing and that is I I grew up and I live in in Saskatoon uh in Treaty 6 territory in Matei community. Um incidentally not in Cory's writing. Uh but I did get to know
37:29
Speaker A
Thomas Hardle who this bill is named after. And I would be remiss if I didn't have the to this opportunity to just acknowledge him and his family um and some of the bravery that they faced as as the first patient with the section 56
37:42
Speaker A
exemption um to walk this path. And I've learned a lot from um sitting with him and learning from him and he really taught me a lot about how much this compassionate access in this case to psilocybin has meant for transforming
37:56
Speaker A
his life uh extending his life so that he had more time with his family with a palative diagnosis. Thank you.
38:04
Speaker A
Thank you Erica. [clears throat] Next we'll go to Nicholas Pope. Hello, my name is Nicholas Pope. I'm a lawyer at Hamid Law here in Ottawa and I've represented dozens of doctors and patients seeking medical access to psilocybin.
38:22
Speaker A
The current medical access path is the special access program and this is not a sustainable path for three reasons.
38:29
Speaker A
First, it results in very long treatment delays. Second, it requires bureaucrats who have never met the patient to second-guess doctor's decisions.
38:41
Speaker A
Third, it puts an enormous strain on Health Canada's small special access program team and hinders them from doing the work that that program was originally set out to do.
38:52
Speaker A
To illustrate these problems, I'm going to tell you about some court cases. First, interference in doctor's decisions.
39:02
Speaker A
My client Jod Lance is an ordinary Albertan, except for one thing. He suffers from cluster headaches. And cluster headaches, according to some accounts, are the most painful condition known to humanity. They're often called suicide headaches for a very good
39:18
Speaker A
reason. Mr. Lance tried dozens of treatments and nothing worked. So his neurologist who happens to be an expert in headaches recommended psilocybin and the neurologist got a second opinion from a chronic pain specialist and an expert pharmacist both of whom agreed. So the neurologist
39:40
Speaker A
applied through the special access program and through that process he spoke on the phone with a Health Canada official and the Health Canada official acknowledged quote safety is established and quote I know it works.
39:54
Speaker A
Despite this, Health Canada refused the application. I took this to federal court and the court found that Health Canada's refusal was unreasonable because Health Canada failed to consider Jod Lance's charter right. Section seven of the charter protects the right to make reasonable
40:13
Speaker A
medical choices on the advice of a doctor. After that court win, Mr. Lance received the treatment and it was highly effective and had no adverse effects.
40:25
Speaker A
But this brings me to the second problem delays. Mr. Lance's neurologist applied for a second course of the treatment, and it was the exact same amount of psilocybin as the first treatment, but he waited for three months and
40:42
Speaker A
received no reply from Health Canada. So, I filed an application in federal court to try to compel a decision. And finally, after five months of waiting, Health Canada approved the second treatment.
40:56
Speaker A
And this delay that Mr. Lance experienced is not unique. Over the past four years, I have filed around 20 applications in federal court to compel Health Canada to render decisions on delayed SAP applications.
41:10
Speaker A
Because approvals can take anywhere from a month to a year. And for someone suffering from suicide headaches or treatment resistant depression and suicidality, these delays can be deadly.
41:23
Speaker A
But the delays keep increasing. And this brings me to the third problem. The SAP team is small. It's only about a dozen people. And they're responsible for approving all sorts of emergency treatments, not just psilocybin.
41:39
Speaker A
And we've learned through recent court filings that psilocybin requests have accounted for approximately 2% of all of the SAP requests, but have consumed an estimated 25% of that program's review resources. So, Health Canada officials are not exactly pleased that they're
41:57
Speaker A
being asked to decide who gets medical psilocybin. It's not their expertise. It's not supposed to be their job.
42:05
Speaker A
Doctors are already accountable to provincial regulatory bodies and those bodies have the expertise and the resources to oversee doctors.
42:15
Speaker A
So in summary, patients should not face months of delay to access medical treatments. Doctors should not need to hire a lawyer to get their patients medical treatment. And Health Canada's SAP team should not be required to seconduess doctor's decisions.
42:32
Speaker A
So where do we go from here? The current system is unconstitutional and harmful to all parties involved. If something does not change soon, the courts will make it change and they will align the law with section 7 of the
42:47
Speaker A
charter. But what would be better? for a judge to change the law based upon the facts of one individual case that comes before them or for parliament to change the law after considering all the implications and hearing from a broad range of
43:01
Speaker A
parties through committees and debate. Thomas's bill is the change we need right now. It will help us move forward to a future where doctors make medical decisions. Health Canada is freed up to do its important other work and patients
43:18
Speaker A
receive timely treatment. Thank you. Thank you, Nicholas, and thank you, Erica. Um Erica um you talked about end of life care and I'd like you to unpack a little bit uh about the research and stories you've heard of how uh different
43:35
Speaker A
societies or different um facilities utilize psilocybin in end of life care. Yeah, thanks Corey. Um, historically, end of life care didn't really fit into the psychedelic research that was going on. And yet, people were using it for things like existential
43:56
Speaker A
distress. And, you know, we fast forward a few decades and change the vocabulary a little bit. And we're finding more and more patients seeking access to uh, psilocybin in particular for this kind of end of life anxiety. Sometimes it's
44:10
Speaker A
difficult to package that or see it in a specific category uh specific medical category and certainly we recognize that is a global issue. Um but both anxiety and depression often moves move into really dangerous categories uh in severe
44:24
Speaker A
categories when faced with an end of a paliotative diagnosis and I think that's some of the places where we've seen health Canada respond to compassionate access but as the previous speaker noted um the system is a little bit
44:38
Speaker A
overwhelmed with requests in compassionate access when we what we really need is some more sustained access and perhaps more sustained research so that we can identify some of the wider cate categories here. Um, [cough] thank you, Erica. Um [clears throat]
44:55
Speaker A
uh Nicholas uh you talked a little bit about some of the the trying uh timelines and um for end of life care.
45:04
Speaker A
I'm I'm thinking of a patient in mind in Ontario where he had a pulmonary um disorder that was going to kill him. And uh he waited upwards of 11 11 months to get a a reply. And what he got back, I
45:21
Speaker A
have in my office is over 10 pages of no offense to lawyers, but legal speak and butt covering uh from Health Canada rejecting a dying man that would like to access the medicine that his physician prescribed. Nicholas, um have you had
45:39
Speaker A
heard cases similar to that where of people um you know dying on us waiting to hear back from Health Canada?
45:49
Speaker A
This is all too common. Uh, and those 10-page refusal letters are what we're seeing nowadays.
45:55
Speaker A
Um, a lot of resources are being spent trying to defend unconstitutional decisions here rather than simply making things work for patients, especially when they're already dying. what's the harm in allowing a patient who's already dying or a patient who's tried numerous
46:13
Speaker A
treatments and is suicidal and and this might be something that helps them uh to try this treatment. So uh these delays are quite avoidable if we the government wasn't so focused on protecting itself from patients charter rights.
46:29
Speaker A
And uh back to Erica uh just a followup question about some of the work that uh you you have done on um some of the the the the benefits of psilocybin kind of a broad question about um where have you
46:45
Speaker A
been surprised that psilocybin has been mentioned as a potential benefit for or kind of a um it seems seemingly every day that there's a new article written about psilocybin there's a new indication um And I know Erica knows all
47:00
Speaker A
things going on with psilocybin. And I'm just wondering if there's anything that has been uh surprised you in the last decade on how psilocybin might be able to be used in our society.
47:11
Speaker A
Thanks Corey. You're uh you you may be wrong about what I know. Um but uh but I've been reading through I think I'm into thousands now of of patient case uh studies as well as testimonials and and clinical records on this topic from from
47:27
Speaker A
a variety of of sources and I mean jurisdictions as well. Um I you know I think that as experimental categories open up psilocybin is being tried in a huge variety of ways but where we are seeing it clustering towards areas where
47:41
Speaker A
we see I think more success and again I'm a historian not a clinician but what I see in these trials um is certainly clustering around some of the categories that we've identified as as challenging complex and often treatment resistant um
47:55
Speaker A
getting at some of the areas that have been difficult to touch uh with with pain relief and We we certainly see the sort of um comparable terms when we think about the opioid crisis and where opioids have not really been able to
48:08
Speaker A
touch things like existential pain or trauma and yet they have been used as a blunt instrument. We've seen some of the challenging uh downstream effects of that where sub substances like psilocybin operate in a very different way and uh these are not meant as daily
48:24
Speaker A
dose uh pharmaceuticals. These are meant to be used in partnership with some form of therapy, whether that's a community-led environment like ceremonies that we've heard about already or whether that's in a psychotherrapeutic environment. That combination changes the relationship and
48:41
Speaker A
I think mitigates against concerns around addiction on top of the other pharmacological reasons why we recognize already that uh psilocybin containing mushrooms and psilocybin extracted from mushrooms does not have a clinical indication for addiction or overdose. Um that doesn't mean that it can't be
48:58
Speaker A
harmful and I think we need to be very mindful and careful about how we promote these substances. Um, and yet they seem to be moving in areas where we've seen persistent challenges in our health care system and persistent expenses in our
49:10
Speaker A
health care system. But I'm not really answering your questions in terms of like the parts that have surprised me.
49:16
Speaker A
Um, except to say perhaps that I think what has been surprising is the the way that we see history playing itself out again. Um and again to my previous comments, I think that hopefully we have an opportunity to recognize what we've
49:32
Speaker A
learned from the past and move forward rather than um descending back into a moment where we put psilocybin far behind some kind of regulatory wall where we can't access it and then people go to great risks to try to find ways to
49:46
Speaker A
solve this kind of pain that they're experiencing. That's a good segment, Erica, because um I'd like to hear from Nicholas on on the legal side of things is that our current framework where we can access legal psilocybin if you get
49:59
Speaker A
the bureaucrats to sign off on it. And that's great. And I I I'm happy that we have a program at least that will help some of those patients. Um but for the the mass uh amount of self-medicated use
50:12
Speaker A
out there as people are finding it either online or some of the dispensaries out there but for the portion of the population that will not break the law they will just not have access to this medicine. So that is the
50:23
Speaker A
only um group of people that our current regulations that are are stopping is the law-abiding people. Um, Nicholas, do you have comment on what happens in society when we have um an unjust law getting broken by people or not being broken by
50:41
Speaker A
people that should be accessing this care? Is there a kind of a um a negative effect on one's society when we have lawb breaking um that is common such as this?
50:52
Speaker A
Yeah, I think it's quite troubling that we have a system right now where somebody who's relatively healthy and just wants to try some psilocybin mushrooms for recreational purposes can easily go and purchase it. They could walk into a
51:08
Speaker A
shop, no police officer is going to stop them for simple possession and they can try it. But the people who are in the worst situations here who need a therapist support who are who who actually truly need this, they're the
51:21
Speaker A
only ones in society who cannot get it because the therapist won't do it unless it's done legally and it shouldn't be done without uh proper GMP psilocybin and psilocybin that that you know the dosage of. Um, and I think that's
51:36
Speaker A
extremely troubling for society, especially because then many people out there on the street thinks psilocybin is legal and don't understand that the people who need it most can't get it.
51:46
Speaker A
Thank you. Thank you. Our next witness is Roya Barian. Go ahead. Good afternoon everyone. My name is Roya Bargain. I'm a scientist representing Shields Pharma Inc., a Health Canada and GMP approved pharmaceutical contract testing and manufacturing company based
52:20
Speaker A
in Markham, Ontario. I would like to thank the honorable member of Parliament, Cory Tucker, for introducing Thomas bill and advocating for greater access of psilocybin assisted therapy for patients across Canada. But before discussing science, pharmaceutical standards or regulatory reform, I want
52:36
Speaker A
to address something far more important. The patients who are waiting. Across Canada, individuals are living with treatment resistant depression, post-traumatic stress disorder, end of life psychological distress, and other serious mental health conditions. Among them are our veterans whose service to
52:53
Speaker A
this country deserves our deepest respect and whose mental health deserves meaningful treatment options. For decades, anti-depressants such as SSRIs and SNRIs have played a central role in mental health care. But the future of mental health care cannot be
53:07
Speaker A
limited to conventional medication when scientific research has demonstrated the therapeutic benefits of alternative treatments.
53:14
Speaker A
Psilocybin assisted therapy represents a major advancement in mental health care. Clinical studies have demonstrated significant reduction in depressive symptoms and end of life psychological distress with additional evidence of therapeutic benefit for anxiety and substance use disorder. Scientific evidence continues to demonstrate the
53:32
Speaker A
therapeutic benefit of psilocybin assisted therapy reinforcing the need to expand patient access through safe medically supervised care. At Shields Pharma, our work focuses on the development and manufacturing of naturally derived botanicals psilocybin.
53:47
Speaker A
From cultivation through encapsulation, every stage of our manufacturing process follows rigorous pharmaceutical standards supported by comprehensive analytical testing and quality assurance to ensure product consistency, potency, and safety. But what is the value of developing a safe quality control
54:04
Speaker A
medicine if the patients who who may benefit from them cannot access them? This brings me to Health Canada's special access program. Till this day, access remains uncertain with patients facing delays in the possibility of denial, even when physicians have
54:18
Speaker A
identified a medical need. According to Health Canada figures reported to Parliament, psilocybin special access program approvals declined from 119 in 2024 to 51 in 2025. That's approximately a 57% decline in annual approvals.
54:34
Speaker A
While application also declined, these figures raise an important question about patient access. Behind these numbers are veterans living with psychological trauma, patients who have not found relief through existing treatments, and individuals facing terminal illness who deserve dignity and
54:48
Speaker A
compassion and care. When a physician identifies psilocybin assisted therapy as an appropriate treatment option, patients should not face prolonged delays, uncertainty, or unnecessary barrier to care. For those facing life-threatening illnesses, time is precious and and that time can never be
55:04
Speaker A
given back. This raises a fundamental question. Why is psilocybin accessible through unregulated sources while patients seeking safe quality controls psilocybin treatment face barriers to medical access? As a scientist, I recognize the importance of regulatory oversight, rigorous analytical testing,
55:21
Speaker A
and pharmaceutical standards. But patient safety and accessibility must go hand in hand. This is precisely why Thomas bill deserves Parliament's attention. Bill C286 proposes amendments supporting the medical use of psilocybin and psilocin. Thomas Hardle's experience reminds us why this matters. While
55:38
Speaker A
living with stage 4 cancer, he found a meaningful relief through psilocybin assisted therapy. Yet later faced the loss of access to the very treatment that help that had helped him. Canada already has the scientific expertise, the pharmaceutical and manufacturing
55:52
Speaker A
capabilities, and health care professionals to advance psychedelic medicine responsibly. As Parliament considers Bill C286, I ask that we remember the patient at the center of these decisions. Together, we call for an end to unnecessary denials and prolonged delays and for a greater
56:07
Speaker A
access to safe evidence-based psilocybin assistant therapy. Thank you. Thank you uh uh for your testimony. um questions. I I've been I was lucky enough to be through the Shields Pharma facility, a very impressive um facility you built in Ontario. Um could you um
56:27
Speaker A
kind of uh explain to the the audience uh a little bit about the licenses licenses that you have, the processes it took to get to where you guys are right now as a facility.
56:38
Speaker A
So Shields Pharma, Inc. has we're both a Health Canada and GMP approved contract testing lab. We hold a control substance dealer license allowing us to manufacture, test and produce psychedelics from psilocybin to MDMA to DMT. Um with that is that we went
56:55
Speaker A
through the applications of Health Canada. Took a year for Health Canada to audit us. Um we are FDA registered. So hope hoping to um expose our our opportunities in the states. But that being said, we still face a lot of
57:12
Speaker A
barriers with Health Canada. We after three years of R&D, extensive R&D work with our psilocybin product. We recently just got an email of um from Health Canada stating that we have to um report the amount of psilocybin in our wet
57:26
Speaker A
mushrooms. And anyone in this game knows that 98% of um of wet mushrooms is is actually water. Like it's it's all water content.
57:37
Speaker A
So if I I hope we see more knowledgeable bodies in Health Canada knowing where to navigate and how to report um these control substances because right now we have a difficulty reporting our wet product because we don't we don't report
57:55
Speaker A
wet product, we do dry. And it's kind of a tongue and cheek, but what do you think the processes are for the gray market that is uh out there for their production? And it is it was you know um who knows where the current um
58:12
Speaker A
supply of silicon is coming for some of the gray market. And this is where I have great concerns about the current regulation in Canada drives people to the legal um side of things. And I know that uh Chilled Pharma the the processes
58:26
Speaker A
that you have um um in house is is is immensely better than what we currently have in the gray market uh services out there. But um it's I guess the question I have for you is more back to health
58:41
Speaker A
Canada because um you know there's been a lot of talk in Canada about the important importance of about sovereignty and in Canada about diversifying our trade and our economy and it seems like we have some people in government get that and then other
58:59
Speaker A
groups and departments such as Health Canada that will put up more roadblocks it seems for some of our Canadian entrepreneurs, or Canadian science or Canadian facilities um without the understanding that what they're up against. Um so I guess the
59:15
Speaker A
question to you would be um what would you tell what would you like health Canada to know about psilocybin that for whatever reason is missing when you have your dealings with them right now?
59:29
Speaker A
Well, I would tell health Canada it's much safer than the drugs right now being used in public. one being ompic. I don't think um I mean psilocybin is much safer than a lot of drugs being publicized by um by pharmaceuticals. But
59:44
Speaker A
the main difference with legal versus illegal market is definitely the safety of the product. We do comprehensive analytical testing meaning from sports encapsulation. We're doing validation.
59:56
Speaker A
Three conse three consecutive batches have to show um have to be the same. We do stability testing. We do microbial. I can assure you with a lot of these illegal markets even testing it in our R&D phase, the microbial didn't pass and
60:13
Speaker A
what it's what it said on the label stating that it had psilocybin. It really didn't. So heavy metals was was also present where when we do our analytical testing, we assure that these types of factors are eliminated to
60:28
Speaker A
ensure product safety. And for the viewers, um, can you walk us through, um, at Shields Pharma, uh, a batch of mushrooms? What what does that look like in the kind of rough production side of things and and the
60:42
Speaker A
different stages that you guys go through and maybe a little bit on your testing on wherever you can share that's not sensitive for commercial purposes?
60:50
Speaker A
Great. So, we start with spores and then we with the three years of development, we've optimized our liquid culture. So we have eight um psilocybin strains but from that we um do grain inoculation and once mycelium is colonized we then do
61:08
Speaker A
substrate inoculation and both grain and and substrate is is made in house. Once that's done depending on the strain it has to go through its own environmental conditions and parameters which it took 3 years to to understand. Um that being
61:24
Speaker A
said, once we've harvested it and depending on the batch, if it's finished its whole um time, we then dry it. Once drying it, we mil it and then we send it off to our in-house lab. And once that's
61:38
Speaker A
done, um that includes the potency. Again, we do heavy metal even though it's not needed and we send it off to microbial. Once that's done, we then encapsulate it. We've done stability data as well ensuring that our product
61:52
Speaker A
does not degrade and the quality is kept within a year. Mark fabulous. Well, just um I I would say that Canadians need Canadian uh psilocybin and at your facility um which is Canadian-owned um from workers that are that are
62:11
Speaker A
Canadian, producing Canadians psilocybin for Canadian patients for the benefit of our population is what needs to happen.
62:18
Speaker A
And that's what we're all very hopeful with Thomas' bill that would usher in a day that Shields Pharma would be uh busy producing the medicine that our society needs. Thank you for your work.
62:31
Speaker A
Thank you. I'd like to call up uh Spencer Hawkwell and Kamaya Lawrence next. We're just going to take a little pause.
62:56
Speaker A
We're going to Damn, I was ready to go. I know. Me, too. [laughter] We could just steal it a bit longer.
63:24
Speaker A
[snorts] To be honest, I thought we would each like Me, too. I was kind of hoping we'd all be around the table and that thing would spin around and just go. Yeah, that would have been nice.
63:47
Speaker A
Take a picture of my thing. Yeah, go for it. Where are you located? You guys are the ones providing that clinic for I know you're going to operate in Calgary, Alberta, which has all their extra regulations going on.
65:00
Speaker A
Thank you. You too. Yeah. Yeah. Yeah. How long was good? I like that. Oh.
66:04
Speaker A
We're almost That's on. If I could just ask everyone to take their seats. That's red is on.
70:05
Speaker A
Okay Spencer. Okay. Good afternoon. I'm Spencer Hawkwell, president and CEO of Therosil, a national advocacy, research, and training nonprofit founded in 2019.
70:19
Speaker A
Therosol was response to foundational research from John Hopkins, NYU, and UCLA that showed that a single dose of psilocybin was associated with clinically significant decreases in end of life- distress. That's the combination of depression, hopelessness, and demoralization that comes with an
70:35
Speaker A
end of life diagnosis. This was two decades after seriously ill patients fought and won in court for their right to medical cannabis and three years after patients had gone to court and fought for their charter right to medical assistance in dying. Both
70:50
Speaker A
instances they fought and the courts agreed. The pattern is clear. Time and time again the courts have the courts have recognized section 7 rights for patients who are trying to seek access to currently illicit treatments with the support of their doctor. Without that
71:06
Speaker A
right, we are left with serious contraindic or contradictions where patients have the right to die but not the right to try things like psilocybin therapy. That's unacceptable.
71:17
Speaker A
Now, I met Thomas whom this bill is named after when he reached out to our organization for support with the section 56 and to be the lead plaintiff on a court case that would challenge the prohibition of psilocybin.
71:29
Speaker A
Thomas knew that his time was limited. So he made that compassionate plea to the Minister of Health at the time for a section 56. He became an advocate not only for himself but for the many other patients who would come behind him
71:40
Speaker A
seeking access to psilocybin. Thomas's courage and persistence earned himself the first section 56 to use psilocybin and allowed in that same year about 50 other patients to access psilocybin.
71:53
Speaker A
Now when these patients got their exemptions, there was a problem. How could patients access psilocybin without trained health care professionals?
72:01
Speaker A
So, we requested section 56s for health care professionals as well, including Dr. Bruce Tobin, who would go on to be Thomas's therapist.
72:10
Speaker A
We presented our argument to the Minister of Health that these health care professionals should be trained and have access to psilocybin, and the minister agreed and granted those exemptions. And with that, we launched our first training program, which
72:20
Speaker A
allowed these health care professionals to go on and treat patients. Since then, we have trained about 1500 healthcare professionals across Canada and in about 15 countries. Because of that training, Canada now has the foundation of legal professionals that are able and ready to
72:35
Speaker A
provide psilocybin assisted psychotherapy. The only thing is missing is a legal pathway to do so. Now, these people are trained to support patients through the current legal channels like the special access program. But let's look how narrow that access is. In 2025, Health
72:52
Speaker A
Canada's own report on substance use found that over two million Canadians had access psychedelics.
72:59
Speaker A
That is in stark comparison the 55 patients who got access to psilocybin through the special access program. 2 million to 100 or to under 100 to 55.
73:11
Speaker A
Psychedelics are not hard to find as we all know. On my walk here this morning, I passed a store. You can buy them online and have them shipped to your house. And I looked on Google Maps and I
73:22
Speaker A
would encourage other people to do it. Within about 5 minutes walking, there are 12 facilities around Parliament here.
73:29
Speaker A
But patients are not coming to us looking for a mushroom shop. Many of them are incredibly sick and vulnerable and they're looking for support from their doctor. These people have coorbidities. They're on different drugs. They need a doctor's support and
73:42
Speaker A
a therapist's support. But when they try to access psilocybin through the legal route, that is where all the problems begin. So, let's use an example of Pete Pearson, a man from Sarnia, Ontario with pulmonary fibrosis. He did absolutely
73:55
Speaker A
everything right, and I've supported hundreds of these applications. And this one specifically was a slam dunk.
74:02
Speaker A
However, Health Canada through the special access program made him wait an entire year and after waiting, denied his access.
74:10
Speaker A
Soon after, about a week after, to be exact, he applied for medical assistance in dying and was approved. too sick to live, not sick enough to try psilocybin.
74:22
Speaker A
Pete, however, was able to find help. A doctor and therapist, both who had been trained through Theosome, were willing to stand by him even after the only legal door available had been closed on him.
74:34
Speaker A
Still, our current system has forced a dying man to buy an illicit substance from one of these shops with no other way and also forced two trained health care professionals to put their license on the line to keep a patient safe and
74:47
Speaker A
do the right thing. This cannot be how dying people in Canada get access to psilocybin. We need a Canadian solution to the lack of access to psilocybin. The special access program has failed patients and doctors time and time
75:00
Speaker A
again. I urge the government to support this bill and to develop better regulations that would help patients access psilocybin with their trained healthcare professionals. We cannot rely on pharmaceutical companies to bring these drugs to market the traditional way. We need better solutions. They are
75:16
Speaker A
too expensive and restrictive and some of these companies I will put out there have have quoted treatments costing around $50,000.
75:24
Speaker A
That price tag is just not accessible for Canadians in the future. We have the ability and opportunity to be a leader, an an international leader in psychedelic research, advocacy, and training. And I believe that the only solution is that our government act with
75:38
Speaker A
compassion and create a unique Canadian pathway that gives doctors and patients the access to this life affirming care.
75:45
Speaker A
Thank you very much. Thank you, Spencer. And we'll hear hear from Kamaya Lawrence. Hello, my name is Kamaya Lawrence. I'm a clinical researcher with a master of science and neuroscience and direct experience in designing and executing psilocybin assisted therapy, sorry,
76:05
Speaker A
psilocybin assisted therapy clinical trials. Alongside that research, I work closely with patients and advocate for their access to regulated care. I'm honored to appear today on behalf of Theosil and the patients we advocate for. Many of our patients share a
76:21
Speaker A
feeling of being stuck. They feel caught in distressing thought loops from either a persistent depression, a terminal diagnosis, complex trauma, or chronic pain. The standard treatment is usually anti-depressants, but they can take four to six weeks to take effect. And for
76:36
Speaker A
about onethird of these people, they don't work at all. For someone who is dying or in crisis, that's weeks of suffering we should not be asking them to endure. What if a mushroom could help? Research suggests psilocybin may
76:50
Speaker A
increase neuroplasticity, the brain's ability to adapt to change, to form new connections, strengthen existing pathways, and let others fade. Which may be why it shows promise across so many conditions. Rigorous clinical trials have provided evidence that psilocybin assisted therapy can be safely
77:05
Speaker A
administered in a range of populations and indications, including people with cancer related distress, major depressive disorder, chronic pain, and veterans with PTSD. It's unusual for one drug to show potential benefits across multiple different conditions. So why are we not making faster progress? Part
77:23
Speaker A
of that answer lies in funding. Since prohibition, psilocybin research has largely come from two places. Academic research, usually funded by philanthropy, asks broad questions for the benefit of the society. Industry research is designed to prove one company's proprietary product is safe
77:40
Speaker A
and effective. Academics run many studies, but the large, expensive trials that lead to an approved drug are almost always run by companies, and companies will only fund trials for products they own. So, the version of psilocybin that reaches patients will be the one that's
77:55
Speaker A
profitable, not necessarily the one that helps the most people. A common misconception is that clinical trials use whole natural mushrooms. This is not the case. Natural mushrooms are organic and their potency varies from one to the next. Clinical research standards are
78:11
Speaker A
built around single uniform molecules. So trials use either botanical extracts or synthetic formulations in pill form.
78:20
Speaker A
The leading candidate for approval is a proprietary synthetic product. The company developing this product has told its investors it's aiming for an annual cost in the range of $50 to $65,000 USD per patient. Yet the very same molecule
78:34
Speaker A
occurs naturally in mushrooms that grow wild across Canada and that can be cultivated, tested, and standardized at a fraction of that cost. Why should a naturally occurring mushroom remain prohibited while a patented copy of the same molecule is approved?
78:50
Speaker A
There is a lot of red tape standing in the way of a regulated path to psilocybin. But there are very real people who are in need right now. We cannot let paperwork get in the way of people's chance at peace in living and
79:02
Speaker A
in dying. Today, I'd like to share in their own words the experiences of people living with cancer who have shared their words for you to hear today.
79:11
Speaker A
Deian Katang shares that following her two psilocybin treatments. There remains a sovereign peace and the intimate certainty that I am capable of crossing the end of my life in complete serenity, knowing that now I live a tranquility that gives me back the freedom to fully
79:26
Speaker A
inhabit my existence until the end. 65-year-old Robert F from Montreal shares, "I can unequivocally say that the two treatments I've had to date have had a huge impact towards a greater sense of my well-being." Janice Hughes shares, "Five years ago
79:45
Speaker A
this month, I was considering applying to MADE to put an end to the severe mental and spiritual anguish I was experiencing as a result of a terminal cancer diagnosis.
79:54
Speaker A
Instead, I decided to pursue the prospect of relief through psilocybin assisted psychotherapy. Not only did I lose my fear of death, I renewed my appetite for life. In the last five years, I have lived more fully and with greater love for and acceptance
80:09
Speaker A
of myself than in the previous 65. These are the real people that this conversation is about. Not patents or paperwork, but people who do not have time to wait. I began by asking, what if a mushroom could help? For the people
80:25
Speaker A
whose words you just heard, it already has. The priority must be a real pathway to access, one that includes whole natural psilocybin, and it must be backed by research that reaches those at end of life and our veterans. They
80:38
Speaker A
deserve their chance at peace. Thank you to Thomas Hardle. And thank you. Thank you for both of yours testimonies today and thank you uh for Theosols uh leading the charge as a nonprofit advocacy group um that have trained um
80:58
Speaker A
hundreds of well over 1500 doctors in Canada or uh healthc care prof uh professionals. I I know that the work that you guys have done has made uh huge differences in patients lives. So, thank you for doing that. Um Kamaya, I have a
81:15
Speaker A
question about um some of the trials that are could be started out there and what could the next uh trial from a a Canadian institution with a Canadian uh researcher with Canadian patients? What would ideally you think that we should
81:32
Speaker A
be looking at next with psilocybin? trials do you think should come? That's a fabulous question. I think I could speak on that topic for way longer than we have today. Um, but I think it would be absolutely fabulous if we could
81:46
Speaker A
have whole mushrooms in a clinical trial targeted either at patients who are at end of life again for this distress that we find all too common or for veterans who are dealing with perhaps a different but related kind of distress due to the
81:58
Speaker A
traumas that they may have incurred during their service. I think that would be most wonderful. And I also would encourage all researchers to incorporate qualitative data into their trials. That is ask people how they felt about their treatment in their own words as opposed
82:12
Speaker A
to relying solely on quantitative measures. And uh Spencer, if um if you could um um start a trial um tomorrow um for the viewers online, what what would that look like? as in um if you could walk us
82:32
Speaker A
through you talked about the training of these uh trained uh health care professionals when they're utilizing psilocybin. Can you walk me through what a trial would look like for a patient?
82:42
Speaker A
So a patient would see it see an ad uh saying advertising here's a study. Can you walk through what typically happens or what should happen in a sil 7 study in in the kind of the next kind of
82:53
Speaker A
progress progression? Yeah, absolutely. So patients trying to access psilocybin right now um as we mentioned have to go through either the special access program or through clinical trials many of those clinical trials as Kamaya mentioned are designed by drug companies in order to get a drug
83:10
Speaker A
approved not always to support what the patient wants um or to support how it's used many times underground. So you know what an ideal trial might look like is one that is actually developed by and for patients. This is exactly what we're
83:23
Speaker A
working on with the right now both for veterans and end of life patients. going to them many of the people who have accessed psilocybin through the special access program or through section 56 and have their own experiences. So what that
83:35
Speaker A
might look like is you know the patient signing up for a clinical trial operating either individually or in group therapy and some of the things we've heard back are a lot more kind of focus on the environment that they're in
83:46
Speaker A
the set and setting being with trained health care professionals and sometimes even being in cancer groups. Uh I've had the great privilege of being part of a cancer group study um being a facilitator there and it's amazing to
83:58
Speaker A
see how when these patients come together and get treatment uh how much they benefit from each other's stories each each other's lived experiences.
84:06
Speaker A
This is not happening right now uh in the pharmaceutical sector. It's something that we have to do from a community perspective or an academic perspective. Uh and we would encourage you know continued or increased let's say funding for these sorts of studies
84:18
Speaker A
that really are patient centered. It's a word we've used for, you know, for decades now, um, but have struggled to put into practice.
84:30
Speaker A
And some training opportunities and can can you um tell the audience a little bit more about uh some of the the programs that the offers?
84:40
Speaker A
Absolutely. So we do training not only in Canada but also in the US um in Australia, in New Zealand and for people in many different countries across Europe and the world. Uh I'll just mention that some of those countries are
84:53
Speaker A
accelerating ahead of Canada um where we were the leaders back in 2019, places like New Mexico where we're offering training, uh actually have set up regulations where they're able to, you know, patients are able to get access to
85:06
Speaker A
whole mushrooms and clinics can provide therapy. the same in Australia where the TGA has an approved prescriber program and in New Zealand. In almost all of these places, they don't need to go back to, you know, Health Canada or to their
85:19
Speaker A
their health um to their regulators to ask on an individual patient basis. Uh doctors or psychiatrists are just given the ability to treat patients. So when it comes to what we offer is we we offer training for health care professionals here in
85:34
Speaker A
Canada but also abroad to understand how to best prescribe um support through through therapy um the patients that they're going to be treating no matter where they are. Um so you know we've done that for the last couple years and
85:48
Speaker A
it's really what's been responsible for for patients getting access. It's only through trained health care professionals that that people get the care they need. And how does the patients if if a a viewer has questions or maybe the viewer would like to take
86:00
Speaker A
part in a study? How do they find theel or how do they find the trials? I I don't have the answer. Is there website or what what what's best for someone that would like to take part in a trial?
86:11
Speaker A
Yeah, absolutely. So they can come to www.therrail.ca. uh we support both healthcare practitioners find the right training for themselves and also patients uh find legal avenues whether it's through section 56 the SAP uh or through clinical trials.
86:30
Speaker A
Okay, thank you. Uh we'll go to our next group of speakers, Austin Miller and Erica Camemer.
86:54
Speaker A
for better. Okay. I'd like to ask Austin Miller to go first. Okay. Good afternoon everyone. Thank you Corey, everyone else for putting this together and for everyone for coming out today. It's uh quite the impressive group we have here. My name is Austin
87:24
Speaker A
Miller. I'm president of Blue Stem API. We're a Canadian psychedelic medicines company focused on research, advocacy, and treatment particularly around botanicals psilocybin.
87:36
Speaker A
And we're also a social enterprise which is important. It means we have a triple bottom line, financial of course, but also environmental and social uh operating in the public good.
87:47
Speaker A
And um to that end, we're using natural mushrooms and combining pharmaceutical methods to such as, you know, micronization, homogenization, etc. to essentially uh thread that needle uh with having uh whole plant extract or biomass uh but meeting the standards of
88:06
Speaker A
standardization that's required uh for modern medicine. I also serve as chair of Canada's psychedelic industry association and the association welcomed the tableing of Thomas' bill back in the spring. You can read our um press release on that at scikan.ca. We've got
88:24
Speaker A
several member companies represented here today. So, I'm going to let them speak for themselves and focus my comments on our own uh perspective.
88:32
Speaker A
Um really, I'm going to take just the next five minutes to make five key points in support of C286.
88:41
Speaker A
The first is all the science and all the public opinion supports this. Um it's incredibly safe. It's remarkably effective, as you've heard from others.
88:50
Speaker A
I won't get into that, but I will say that we've done some recent polling and it shows that a majority of Canadians support medical access to psilocybin across all age groups, different political leanings, uh you name it. Um
89:03
Speaker A
and plus because of this, as been alluded to, there's already a psilocybin market. So the question isn't should we have access, the only question is should we have a safe and regulated market or one that is not.
89:22
Speaker A
So second, this is just good public policy. We're in an addictions and mental health crisis costing thousands of lives and costing the country over a hundred billion a year in policing, courts, hospitals, lost productivity, all which could be prevented.
89:41
Speaker A
And what's more, at a time when we're elbows up and pursuing economic diversification, the government should be encouraging and supporting emerging domestic industry, certainly not hindering it.
89:55
Speaker A
Some of the world's leading psychedelic companies are from Canada, most of them actually. Uh some represented right here in this room today.
90:04
Speaker A
And beyond helping society and reducing suffering, they can attract billions in direct investment, create thousands of jobs, and spur other important economic multipliers.
90:17
Speaker A
Third, the status quo is simply not sustainable. The SAP, as we've heard, special access program, is not fit for purpose. Full stop. And senior healthcare officials have admitted as much to me privately off the record. And so I I look forward to hearing what they
90:33
Speaker A
have to say when this comes to committee. Patients and doctors of course know this all too well as we've heard. Burdisome application forms, long wait times, low chances of success.
90:45
Speaker A
We've actually done some recent ATIP access to information requests. And we see that healthcare has own internal numbers demonstrating increasing weight times and decreasing approvals.
90:56
Speaker A
And on top of all that, for those working of us working in the space, they censor our websites. So anytime we try to simply uh direct patients or doctors to a legal pathway, uh they shut us down.
91:12
Speaker A
So that's where we're at with the SAP and we need to change that. Uh in the in the meantime, I'd be remiss not to mention that that is what we're currently dealing with. So until we change it, we're trying to make things
91:22
Speaker A
better. So at Blueest, we developed a digital health platform that automates the entire process uh the application as well as connecting patients with uh doctors suppliers clinics researchers, taking it down from days and hours to minutes. Uh it's free, it's
91:35
Speaker A
easy. Um so if anyone needs help or you know someone needs help or you're a practitioner that wants to treat your patients, please speak to me after or you can go to blueest.co and we can help you out.
91:49
Speaker A
Now fourth, this is this is really important I think is we really support and appreciate want to highlight the dual use or the dual uh nature of this uh bill both in terms of rescheduling the substance and uh increasing the
92:01
Speaker A
service standards both in terms of timelines and guidance. Uh we've got firsthand experience with this. you know, waiting months, years, uh, sometimes for licensing and permits for research and for treatments. Um, and then and then hitting a black black box
92:15
Speaker A
when trying to get information from the department. Um, so it's really important that we uh that we address those service standards, but equally important when we're addressing those and rescheduling this substance that we really got to do a lot of
92:31
Speaker A
deliberate and hard work on the regulatory side because a lot remains to be seen to how this still how this rolls out and what this actually looks like on the ground and that's um that's really where the magic happens or the devil's
92:43
Speaker A
in the details as they say. Um so we need to be very deliberate about that.
92:49
Speaker A
uh when it comes to things like training dosing staffing accreditation reporting botanicals versus synthetics, etc. So, and you know, and more, it's not going to be a one-size uh fits all solution either. That's really important to point out. Uh we're going to need diversity
93:04
Speaker A
there, but we're also going to need clarity and clear guard rails while at the same time not uh shutting down any uh viable options.
93:14
Speaker A
Fifth, as been mentioned, it's worth reiterating. We need more public research funding into psilocybin. Uh, full stop at Blue Stem are working with other groups and stakeholders on pilot programming for First Nations, veterans, first responders, and others. Um, as I
93:32
Speaker A
said, it's in the public good and we need support and uh, there is lots of support in society and elsewhere, but not as much from where it should be coming from, which is the tri councils and other pools of federal money.
93:43
Speaker A
Um, again to that end, if anyone's interested in joining a pilot or helping in any way with fundraising or uh volunteering workplacements research etc., please reach out to me and we can talk about that. And of course, I'd be
93:55
Speaker A
remiss not to say, sign Cory's petition. Every 25 signatures allows him to stand up in the house and raise this again and again and again until we get it. Okay.
94:06
Speaker A
So, that's uh it for me except for one final point and I'm going to I brought a little visual here to drive this home.
94:13
Speaker A
So bear with me. 1974. That's the year that Canada first criminalized psilocybin. In that year, doctors still smoked in hospitals. Computers filled entire rooms. Kids drove around gleefully in the back seat with no seat belts. That was a different time. And we wouldn't
94:34
Speaker A
put up with any of that now. So why are we still accepting outdated and uninformed thinking from that time on silicide?
94:42
Speaker A
we've moved on and our uh our laws need to as well. So, this is not a partisan issue, but it is a political issue. It was political when it was first banned and it's going to take political will to
94:55
Speaker A
rectify that. So, we all need the courage to meet the moment here and uh do what we can to vote for this bill to support the bill in any way. So, thank you very much.
95:06
Speaker A
Happy to take any questions. Thank you, Austin. And we'll go to Erica Caxar Merrick.
95:17
Speaker A
Hello. Uh, thank you. Uh, hello. Uh, my name is Erica Kesmar and I'm a PhD candidate at the University of Toronto working under the supervision of Dr. Joshua Rosenblat.
95:35
Speaker A
Our lab focuses on novel treatments for mood disorders and I've had the privilege of working in psilocybin research for depression for the past five years.
95:46
Speaker A
Over this time, our lab has completed multiple psilocybin clinical trials, including Canada's first investigator initiated clinical trial of psilocybin for depression.
95:57
Speaker A
We have been at the forefront of advancing psychedelic research in Canada, not only bringing this research to Toronto and expanding opportunities for patients to access these treatments through clinical trials, but also by building the clinical infrastructure and research expertise needed to move the
96:14
Speaker A
field forward. Through this work, we have helped position Canada as a global leader in clinical investigations of psilocybin and other psychedelic assisted therapies. Importantly, our research has sought to move beyond the populations traditionally represented in these trials. We've
96:34
Speaker A
included individuals who have been historically excluded from this research, including those with significant treatment resistance, personality disorders, suicidality, and bipolar disorder. Most recently, we've completed the largest clinical study of psilocybin in bipolar disorder to date.
96:52
Speaker A
When while these contributions are important from an academic and a scientific perspective, what is most encouraging to me are the stories that we have seen in our patients.
97:03
Speaker A
Across our studies, we've observed reductions in depressive symptoms and improvements in quality of life. But beyond these outcomes that we can quantify, there are individual experiences that have stayed with me.
97:17
Speaker A
One such story is from one of my patient participants who told me that we had given him his life back.
97:24
Speaker A
For a long time, he felt as though he was simply going through the motions of life rather than truly participating in it. Following treatment, he described being able to reconnect with and enjoy the life that he had worked so hard to
97:38
Speaker A
build. As a psychedelic researcher who has spent the last few years working in the space, these are the experiences that continue to inspire me. I've had the privilege of working with our participants and seeing the people behind the data points. Having sat with
97:53
Speaker A
many of the individuals throughout their psilocybin treatments within our trials, I've been able to hear their stories and witness changes in their lives that extend beyond what we can capture through clinical trial measures. These experiences have given me tremendous
98:08
Speaker A
hope and optimism about what we may be able to achieve for mental health care in Canada within our lifetime.
98:17
Speaker A
Looking ahead, our work within the academic setting focuses on three key areas of psychedelic research. Exploring new clinical indications, optimizing treatment protocols, and better understanding the underlying neurobiological mechanisms of these compounds.
98:34
Speaker A
address the mental health crisis. Despite the progress made over the past several years, there are there is still so much that we don't know about psilocybin and psychedelics more broadly. There's an enormous opportunity to advance this knowledge, but doing so
98:48
Speaker A
will require continued investment, collaboration, and support from both our academic and government institutions. We've already seen the possibilities when we are able and willing to push beyond traditional research boundaries, like when including more complex real world patient populations in our trials
99:05
Speaker A
or when building infrastructure needed to deliver these treatments safely and responsibly. I truly believe that Canada is well positioned to continue to play a leading role in this field through continued collaboration, investment, and a commitment to rigorous and inclusive
99:21
Speaker A
clinical research. we have the opportunity not only to advance our understanding of psychedelics, but to translate that knowledge into meaningful improvements in mental health care for Canadians. Thank you.
99:36
Speaker A
[laughter] Thank you so much for your testimony. Um, first question for Austin. Um, I first off, thank you. Thank you for stemm the different um, uh, companies that are operating in the psychedelic um, industry in Canada. It's not an easy
99:53
Speaker A
time. It's not easy um any time to be an entrepreneur but to be an entrepreneur during uncertainty around regulation um around some of the the excitement about about the science- which we know that psilocybin can help people suffering
100:08
Speaker A
from mental health and addictions. On the business side of things though, Austin, if um not to diverge anything that of that's that's uh sensitive for commercial reasons, but um the 25 mgram compass molecule that is rumored to be
100:23
Speaker A
in the price range of 25K US would you would be you I would suspect your your product will be below 25K. Is that confirmed?
100:32
Speaker A
Yeah, orders of magnitude below. Yes. Um I mean there's different Yeah. without getting into specific because there's certainly different ones as I mentioned there's extracts there's there's biomass capsules there's um you know there's there's there's micro doses we haven't talked about much of that
100:45
Speaker A
today but there's you know there's so there's different doses as well not just 25 milligram equivalents um but that being said just with your example and of course it's worth pointing out as been as been said earlier it's this is not
100:56
Speaker A
[clears throat] a standalone product this is goes hand inhand with therapy and therapy is actually the larger cost or should be or you know typically is unless you're really jacking the price of the molecule uh to pay back some uh
101:07
Speaker A
some uh some some shareholders. It's basically $5,000, let's say, at the top end, maybe. Um and that would include that would include therapy. So, and and it could be less. I mean, there's a range, but yeah. So, we're talking
101:20
Speaker A
substantially less. Yeah. And CAD, not USD. Yes. And and it's an important part. Um and you you referenced uh the pop culture reference of elbows up, but I can't think of anything that would weaken uh the the strength of any
101:36
Speaker A
country that losing supply of their medication. And here's an opportunity uh through psilocybin that we can help companies um throughout Canada, Blue Stem being one of them, hopefully bring a molecule to market that can help people. And we just in our country
101:53
Speaker A
alone, it's over hundred billion dollars and growing cost to our society, mental health and addictions. And psilocybin will help not all of those patients, but enough of them that we know that it would make a difference in our society.
102:08
Speaker A
And Bluestem is a a corporate partner that is uh been um very helpful in Thomas' bill. I thank you Austin for your support because Thomas would uh be very supportive of what Blue Stem is trying to do is accomplish um something
102:24
Speaker A
that would make I I know Thomas very proud. So, thank you for um being here today. Erica, on on the research side of things, uh we've had discussions in the past about um you know, ongoing studies, but if you were to design a study uh
102:42
Speaker A
with psilocybin um for your personal interests, what would do you think that it should study? What indication or what population do you think it would be most personally interested in in the science?
103:00
Speaker A
I mean, I have a big interest in uh bipolar disorder. As I mentioned, we've just finished our uh a study looking at the neurobiology behind it. My own thesis is focused more on a transdiagnostic symptom of anhidonia. Um
103:15
Speaker A
that is something that affects people uh with depression, with bipolar disorder, with ADHD. Uh very transdiagnostic. Uh so a very personal interest of mine would be really focusing psilocybin research on anhidonia. That being said, I think we have a lot of unanswered
103:33
Speaker A
questions around therapy. How much do we need? How many repeated doses do we need? And just these fundamental ideas that we still don't know. And I think being able to do research into that, that's probably the priority.
103:48
Speaker A
And with Dr. Rosebwalk's um team that that you guys have assembled. C can you tell the viewers a little bit about the the the team and the capacities that you have in Toronto?
104:00
Speaker A
Yeah. Um so we actually have I think the and I could be wrong uh but I think we have the only full-time psychedelic therapist in Canada on our team. She does um most of our doses. We have a lab manager that
104:16
Speaker A
is also a trained psychedelic therapist to step in if needed. We have lots of graduate students working to advance the knowledge and the science. Um we have psychiatrists uh that are trained in psychedelic therapy as well sitting in
104:30
Speaker A
with our patients. Um clinic coordinators, research coordinators. We have a big lab actually about 20 people.
104:37
Speaker A
So a lot of work and a lot of personnel goes into this. And if there is a patient that would like to take tri uh to part in a trial in Toronto, how how do how would a patient find out about
104:47
Speaker A
you? I always recommend clinical trials.gov. Um it is probably the best way for patients to find out about uh these clinical trials. However, uh a barrier um is that they patients do need a referral to the depression center to the
105:04
Speaker A
hospital and unfortunately that can take some time to be processed. So there is that barrier of even if somebody is interested they may not be able to convince their own practitioner to send that referral or they may run into wait
105:16
Speaker A
times. Um so there are some barriers uh to patient participation unfortunately. Excellent. And just last question to Austin. Um if we were lucky enough to have the Minister of Health uh here today uh what would you tell her? What
105:30
Speaker A
would be your two minutes kind of comment on Thomas's bill and and uh uh research?
105:37
Speaker A
I would speak at triple speed saying the people want it, the courts are insisting on it. Uh but more importantly, I think I would say what you already alluded to and what I mentioned in my in my remarks
105:46
Speaker A
as well is a like the savings will represent like the cost that we need for funding this is going to be made up for 10fold in the savings that we get from this. So if you're the health minister
105:55
Speaker A
and you're worried about the population health uh at large, um this is a no-brainer. We're wasting money. We're throwing money at things that aren't working and people are dying and uh we have a way of spending less money on
106:06
Speaker A
things that do work and have very little to no side effects. Um yeah, it's a no-brainer.
106:12
Speaker A
Thank you. And Erica went last question. When you're starting a new trial uh with a patient, um there's precautions with psilocybin, but how how safe do you feel this molecule is in your experience?
106:28
Speaker A
It has demonstrated uh safety and tolerability across many different clinical trials. Uh however, we do have strict in strict inclusion and exclusion criteria because unfortunately it may not be safe for everyone. Um and that has been seen in some community uses. Uh
106:47
Speaker A
so generally in the populations that we are currently studying it is quite safe and tolerable but I can't predict what that might look like in future clinical populations that we study unfortunately because we need to fund more research to
107:00
Speaker A
find out. Yes, we do need to fund more [laughter] research. I I would agree with you.
107:05
Speaker A
Thank you. Thank you. I'd like to call Jessica Vanderhook and Katya Thu up for our next speakers.
107:35
Speaker A
Good. Katia Theu, is she in the Is she here? No. We can pause here, guys, just for a second.
107:44
Speaker A
Where's James? Okay, Jessica, I'll let you start. All right. I'd like to start by just saying that I'm here to advocate on behalf of all of the first responders and military personnel who deserve legal access to psilocybin.
108:37
Speaker A
Thank you, Corey, for the opportunity to share my experience and observations about psychedelics and to explain why I advocate for the legalization of psilocybin.
108:48
Speaker A
My name is Jessica Vanderhook and I believe that I am alive because of psychedelics.
108:54
Speaker A
I've been a paramedic for 26 years and my perspective is both personal and clinical.
109:01
Speaker A
I have benefited from this treatment myself and as a clinician working in psychedelic assisted therapy, I have witnessed profound changes in hundreds of lives.
109:12
Speaker A
After being diagnosed with PTSD in 2011, I tried every treatment offered to me through our medical and mental health systems, but none of the treatments were effective. Not one single one.
109:26
Speaker A
I experienced persistent suicidal thoughts and I used alcohol to cope. I firmly believed that without the opportunity to access psychedelics in another country, I would not be here today.
109:40
Speaker A
During my work in psychedelic assisted therapy, I have supported more than 450 people. I also opened one of Alberta's first psychedelic assisted therapy clinics and I served on the panel of experts to help develop the provincial regulations for
109:54
Speaker A
this care. I am currently the clinical lead at Savvy Mind, a ketamine therapy clinic in Calgary and I see patients on a weekly basis.
110:05
Speaker A
Among the people I have supported, I've observed the following. Equal numbers of men and women have accessed this treatment.
110:14
Speaker A
Approximately 20 to 30% have been first responders or military personnel. Some have been the victims of violent crime, including sexual assault.
110:27
Speaker A
Some have been in their 60s and 70s, which is a demographic I did not anticipate.
110:34
Speaker A
And many have been referred by their family physicians, which I see is an indication of growing awareness among medical professionals.
110:43
Speaker A
In my clinical work, many people have described psychedelic assisted therapy as a last resort before taking their own lives.
110:51
Speaker A
Afterward, they reported not only no longer feeling suicidal, but as a matter of fact, feeling enthusiastic about life for the first time in years and sometimes decades.
111:04
Speaker A
Others have described stronger relationships or marriages, more engaged parenting, renewed professional and community involvement, and a return to interests that they had abandoned.
111:17
Speaker A
These accounts have reinforced my belief that psychedelics can not only benefit individuals, but they can benefit families and communities as well.
111:26
Speaker A
Safety is central to my support for legalization. We now know through research that psilocybin is not only safe when used appropriately, but it's effective for treating mental health injuries and illnesses that our current system cannot effectively treat. I think we can all
111:42
Speaker A
agree that what's currently happening isn't working. Research is currently exploring the potential for psilocybin to assist with traumatic brain injuries, MS, Alzheimer's, and Parkinson's.
111:56
Speaker A
We also have to acknowledge that these medicines were used for thousands of years before our mainstream awareness of them.
112:04
Speaker A
I've learned a lot about trauma and PTSD. And I often joke that I have a lived experience, PhD, in those topics.
112:13
Speaker A
That lived experience has given me the ability to help people understand the power of psychedelics.
112:19
Speaker A
One of the analogies that I've been using to help people understand why psychedelics are so different from what's currently being offered is this.
112:27
Speaker A
Western mental and medical health have been so busy focusing on the brain aspect of these injuries and there very much is a brain aspect that they have forgotten the humanness to these injuries.
112:40
Speaker A
These are injuries to the relationship that we have with ourselves. These are injuries to the relationship we have with others. They're an injury to the way we see ourselves and our relationship with the world around us.
112:54
Speaker A
When we only focus on the brain, we miss this part. It's the equivalent of having a lawn full of weeds and taking a lawn mower to it and calling it good. The lawn looks neat and tidy, and if you don't look too
113:07
Speaker A
closely, you can't see it's infested with weeds. And you know what? There's value to this, to chopping it all down to a manageable size.
113:16
Speaker A
But what's the first thing to grow back when it rains? It's those weeds. They come back. And this is why people continue to struggle with their mental health.
113:27
Speaker A
When we work with modalities that treat the humanness in us, we pull the weeds out by the root.
113:34
Speaker A
The benefit to psychedelics is that not only do they work on the humanness of us, pulling those weeds out by the root, but there's evidence showing that they also help heal the brain as well, making it a true powerhouse.
113:46
Speaker A
I also want to advocate for the inclusion of paramedics in the implementation of this bill. We are not only people who may need mental health care, but we are also highly trained medical professionals with a direct stake in how this care is delivered.
114:00
Speaker A
In my work, I have seen the valuable clinical contribution paramedics make in psychedelic assisted therapy settings.
114:07
Speaker A
I ask that our profession be recognized as a stakeholder and considered for a continued role in care involving psilocybin.
114:16
Speaker A
As a paramedic, I have dedicated my career to saving lives. Today, I ask you to join me in that mission. Thomas's bill isn't just a bill. It's a lifeline.
114:29
Speaker A
This is an opportunity to save lives. Real lives, real people, real futures, real Canadians who are suffering and have lost hope. So, let's give them hope.
114:42
Speaker A
Trust me when I say there is nothing in the world that feels better than saving someone's life and we have the power to make this happen. Thank you.
114:53
Speaker A
Thank you Katia. Foreign deployer. Verizon responsibility. Security program Fore on October. Super leadership. Security International scientific collabor the profession.
118:50
Speaker A
Mercy Let me see. Uh the in English, but we'll I know it'll be in French back and that'll be good for the video purposes.
119:02
Speaker A
So, uh thank you so much for your testimony. Uh you talked about compassion. Um can you give an example of how you feel that we're we're not being compassionate with how we're regulating Silap right now?
119:17
Speaker A
Um France. leaps Thank you. And Jessica, um, thank you for your testimony and more importantly, thank you for your public service. uh for the years of service as a paramedic.
120:24
Speaker A
Uh we ask our men and women to put on the uniform to um help our society, keep orderly and and safe and and uh in emergencies, help people and um we ask a lot of our paramedics and they
120:36
Speaker A
experience a lot of trauma on the job if you can imagine day after day and they are along with all the other groups that would benefit from psilocybin counseling. I know first responders um currently are and will in the into the
120:50
Speaker A
future. So, thank you for sharing that. You talk about the humanness. Um, there's the patients that you help and there's probably ones that stand out.
120:59
Speaker A
Can you st without private details, but give an example of a a patient that has kind of stayed with you and some of the breakthroughs he or she might have had with counseling with a psychedelic?
121:12
Speaker A
Yeah. Um, I have a few actually. I've I've had uh one patient in particular who uh was the victim of a violent crime and um as a result um hadn't left her house in several years and after working
121:26
Speaker A
with psychedelics, not only did she leave her house, but she went on a trip with her family, the first one she'd taken since the crime had happened. Um, I've had, you know, as I mentioned, several of my patients report to me that
121:39
Speaker A
they were going to kill themselves. Um, and that this was their last go. Um, and to see them on the other side of their treatment where they are actually thriving in their lives because I think that's the part of the thing we've
121:53
Speaker A
really been missing is the bar has been set so low. As long as we keep people from killing themselves, we'll we'll call it good. And that's not okay for me. my bar of success is our people thriving in their lives. Um and then
122:08
Speaker A
another client of mine who um really wanted to be a dad. He was really concerned that based on his childhood trauma that he wouldn't be a very good dad and he did a lot of work around that. And um he sent me an ultrasound of
122:23
Speaker A
his son and I I not going to lie to you. I was sitting in the passenger seat of the ambulance and I balled my eyes out because I know that this little boy is alive today and I got to meet him and
122:36
Speaker A
you know he came into the world to a loving family with a dad who wanted him so bad that he was willing to do what it took to get healthy. So these are real people's lives we're talking about
122:48
Speaker A
and we hear these stories of people that that are struggling. Um, and a lot of times it's it's long term. They've been struggling because the western medicines haven't been able to solve the issue. We we we are kind of terrible in our health
123:07
Speaker A
care system that for the most part we don't solve issues. We we we treat it.
123:10
Speaker A
We don't cure it. Um, but cure is sometimes mentioned with psychedelic treatments. Um, have you had cases where uh patients have had breakthroughs from their first treatments? Some of the the early early signs. Can you unpack some of those early wins that you've had?
123:31
Speaker A
Yeah, I've had um I've had patients, clients that have mentioned that doing one one ceremony um was equivalent to 10 years worth of therapy. I I've worked with several patients that could no longer be diagnosed with PTSD.
123:48
Speaker A
Um I'm one of those people. I had treatment resistant PTSD and we were told that that was a life sentence. And now we know that to not be the case. Um so I I've seen many people make progress
124:01
Speaker A
with one and I've I've seen many people where it's taken multiple sessions to get to to where they wanted to be. But either way, it's more effective than what's currently being offered by a long shot.
124:15
Speaker A
And Katya, is there anything you would like to add from the Quebec or sorry, um I know that you're from the University of Ottawa, but uh I know that Miguel is is researching sales hub. I know there's other great institutions across Canada,
124:30
Speaker A
but in the province of Quebec that are specifically working. Is there anything that you'd like to share about their work? I'm really glad you're asking the question.
125:10
Speaker A
imaginada And if there's one one example Apple u as much as not in the the clinic but on the research side for yourself do you hold up one one patient story that is a little bit close to you that hits close
126:08
Speaker A
to your heart or that yes that is certainly certainly uh there is a person that I know that has a uh chronic disease and has turned to psilocybin uh she had to go abroad because the the system is too complex here it takes too
126:24
Speaker A
long and it really did transform her. This is a very close friend of mine and I'm here for her today. So, I say to the government of Canada, please give people hope and uh relax your laws, provide more access. It's time.
126:43
Speaker A
That's awesome. But can you if you remember those words, do it in French for us one more time. Yes. Sorry.
126:49
Speaker A
[laughter] Especially if this is your friend, we'll we'll start take your time because especially if this is very important to you personally. Foreign speech. Foreign speech. Foreign speech.
127:16
Speaker A
the the the support voila. Thank you both. Merci. I'd like to call next uh Ben Shimshun and Ripperty Darda.
128:27
Speaker A
Okay, I'll let you speak first, Ben. Just press the button and you're good to go.
128:39
Speaker A
Press the button. Okay. [snorts] convening this summit and for bringing Thomas' bill forward. I'm grateful to be part of this conversation alongside my fellow speakers and everyone here today.
128:54
Speaker A
My name is Bin Yammen Shimshin and I'm a registered nurse and the founder of Flow State therapy. We're a multi-disiplinary mental health clinic a few blocks from here and I have an incredible team of nurse practitioners, nurses, social
129:07
Speaker A
workers psychologists psychotherapists and administrative staff who keep it all running. In the last 18 months, we've delivered more than 1,200 ketamine assisted psychotherapy sessions. This tells us two things. People are reaching for alternatives, and the model of delivery exists, and
129:28
Speaker A
it's working. Let me start with who we treat. A significant portion of our case load is veterans and first responders living with PTSD and operational stress injuries that conventional treatment hasn't resolved. And we've heard that here today from others. That population
129:44
Speaker A
has shown some of the strongest responses to psychedelic assisted care in our practice. And alongside them, we treat a broad cross-section of adults with treatment resistant depression, anxiety, and trauma. Their professional parents, their professionals, their parents, and public servants. People
129:59
Speaker A
who've completed multiple medication trials and years of psychotherapy without any durable improvement. These are not people looking for an experience. They're people who have run out of options.
130:12
Speaker A
And recently, a veteran finishing up his follow follow-up appointment here at the clinic walked into our conference room unannounced. And he said, "I'm sorry. I didn't mean to interrupt, but I wanted to thank you all." I'd come to believe that all I could
130:27
Speaker A
ever be was a killing machine. Caged in my own body, stuck in a state of fight or flight, in this threat response I couldn't get out of. This work, he said, opened the door to empathy, to love, and to feeling safe
130:42
Speaker A
again. Something he thought he can never be able to feel. What I can tell you is what we've learned from delivering psychedelic assisted care safely, legally, and at scale right here in Ottawa. And psilocybin is the next tool, and we're
131:05
Speaker A
ready for it. The medicine is only one part of the treatment. Safety and results come from everything around it.
131:11
Speaker A
Careful medical screening, real preparation, a monitored session with trained clinicians in the room, and integration therapy afterward. Those of us doing this work understand what it takes to do it well. And here's what stands in the way. When people call us
131:26
Speaker A
about psilocybin, our team has to tell them the truth. The only realistic legal route is a special access program, and it was built for emergencies. A clinician applies for one patient, waits, answers follow-up questions, waits again, and patients wait months,
131:40
Speaker A
some close to a year, and many are told no, even when we and their entire care team know that they'd benefit from this work.
131:49
Speaker A
People don't stop looking for help because the system says no. As you know, psilocybin storefronts operate openly across this country, and that's where many of these patients end up. They don't know what they're taking, who made it, what the doses are, is it safe, and
132:02
Speaker A
they take it alone. And the status quo isn't keeping psilocybin away from people. It's keeping clinicians away from them.
132:11
Speaker A
And that's why I support Thomas' bill. It moves psilocybin out of the most restricted category. So the decision treats the decision rests with the patient and a qualified practitioner and not a case-byase application.
132:24
Speaker A
Speed to treatment matters. I know that all too well. This bill brings people out of storefronts and back into clinical care and it keeps Health Canada's drug review in place on a faster track.
132:39
Speaker A
And as a there are three things I'd ask you to protect. First, botanical options.
132:46
Speaker A
This year, two large phase 3 trials of psilocybin for depression came back positive. But that product is a proprietary synthetic where psilocybin therapy is already legal. Patients have paid tens of thousands of dollars more.
132:59
Speaker A
Standardized pharmaceutical grade botanicals psilocybin already exists in Canada and is already supplied through the special access program. It's more affordable and it's what many patients are asking for. And second, compounding pharmacists. Pharmacists who can prepare consistent measured doses close to the
133:16
Speaker A
patient keep cost down and access local. So this doesn't become something only large pharmaceutical companies can supply. And third, the clinical review and guidance provisions. Health Canada often tells patients to join a clinical trial. And as we know here, trials
133:32
Speaker A
matter and we're doing a lot of it. and we're working to become a research site ourselves. But a trial is research, not a care pathway. And that's what we need.
133:40
Speaker A
So, let's build the guidance and the evidence together. Clinics, researchers, trial sites, sharing what we learn. And I'll close with this. Thomas Hardle spent his final years fighting for a treatment that was working for him. No one in this country should have to fight
133:55
Speaker A
this hard to get care. And everyone in this room is ready to help. So, let's pass this bill and let us do the work.
134:02
Speaker A
Thank you. Thank you. I'll pass it over to Riveri. Thank you. [clears throat] Can you hear me? Okay, it's great. So, thank you for the invitation and for the opportunity to share my perspectives at the summit today. I am honored to be part of such
134:23
Speaker A
an amazing group of presenters and speak about such an important topic. So, good afternoon everyone. My name is Reverend Darda. I'm also a registered nurse and I've been in practice for more than 35 years. Much of that time was spent in
134:37
Speaker A
the public health care system. I personally have seen and experienced the whole system, every gap, every delay, and it's been with every person who falls through the cracks and can end up at the hospital door. I am also the
134:53
Speaker A
founder of Atmasina Psychedelic Healthcare Solutions, an Alberta-based organization that operates under provincial licensing and college accreditation standards to offer regulated access to psychedelic assisted therapy. And I see both the need and the barriers to care every day. Today I'm
135:13
Speaker A
speaking as the board chair of MAPS Canada. We are a national nonprofit charitable organization working on research education advocacy and access to psychedelic assisted therapy.
135:27
Speaker A
Everything I'll share today comes from what I've experienced firsthand. So, what we know is that about a third of people with depression do not respond to standard first-line treatments. These are people who have tried medication after medication and therapy after
135:42
Speaker A
therapy and they're still suffering. In the hospital system, I saw the same people coming back again and again.
135:50
Speaker A
People in crisis who had already tried everything we had to offer. This included our veterans, first responders, our own healthare workers, as well as those with substance use disorder, grief, and distress at the end of life.
136:04
Speaker A
All the usual options often fell short. I have learned that when an individual tells you they've run out of options, that's not a clinical abstraction. It's actually the most dangerous place a person can be.
136:19
Speaker A
So, in my practice, even where psilocybin therapy is legally possible, regulated access is slow, limited, and out of reach for most people, just as members of our panel have pointed out.
136:32
Speaker A
But the need hasn't gone away. And what I have seen is people just aren't willing to wait. Every day they're turning to unregulated storefronts, underground guides, retreats, self-dosing at home, often with no screening, no medical oversight, and no
136:48
Speaker A
trained professionals in the room. That means no one is checking for medication interactions, a history of psychosis, or other medical conditions. No one is there if the experience becomes overwhelming and no one supports the person afterwards to help them make
137:03
Speaker A
sense of it. What I know is that the lack of access doesn't stop people from using psilocybin. It only takes away the safety and that isn't a reason to slow down this work. It's actually the strongest reason to build safe regulated
137:19
Speaker A
access. Now there is a cost to doing nothing. And every time we have nothing to offer, the person pays, their family pays, and the system pays. That cost shows up as repeat emergency visits, maybe a hospital admission, lost work, and lives
137:38
Speaker A
cut short. This also costs providers. Clinicians, including myself, carry moral distress when they know somebody needs more than the system we work in, has nothing more to give and they have nothing more to offer.
137:55
Speaker A
So, what I know is that psilocybin assisted therapy isn't a miracle cure or a recreational trend. It's an important and safe clinical intervention. It includes careful screening, medical oversight, trained therapists, and preparation and integration.
138:11
Speaker A
As we've heard, a growing body of evidence shows meaningful lasting results for people who haven't responded to anything else. And when people have access to psilocybin therapy in a regulated setting, I know the difference is clear. They are screened properly,
138:26
Speaker A
prepared for what to expect, and never alone during that session. If an experience becomes difficult, a trained professional is right there to support them through it. And to me, that is what safety looks like. Afterward, integration support helps people make
138:41
Speaker A
sense of the experience and turn it in turn it into lasting change in their daily lives.
138:48
Speaker A
I see many people who had given up described they feel hopeful again through participating in psilocybin assisted therapy. They've reconnected with family, returned to work, and re-engaged in their own care. I also acknowledge what Jessica stated that many individuals [clears throat]
139:04
Speaker A
tell us it's the first time in years they felt like themselves. And because it happens within a health care system, it's documented, measured, and accountable. So we can all keep learning what works and for whom. Safety comes from the model of care, not just
139:23
Speaker A
the medicine. And that model is exactly what's missing in the settings people are turning to today.
139:29
Speaker A
So what I believe needs to happen is we must f fund Canadian trials alongside realworld data collection so policy can rest on evidence. We must continue to train clinicians to deliver this safely and ethically with clear standards of
139:46
Speaker A
practice. We must create clear timely regulatory pathways so access doesn't depend on wealth location or a special access application.
139:58
Speaker A
I know in our design, equity must be considered with the inclusion of indigenous, rural, and underserved communities, not for them, with [clears throat] them. And as we're demonstrating here today, collaboration with regulators, governments, clinicians, researchers, and people with
140:18
Speaker A
lived experience. We all need to work on this together. So everyday health care providers sit across from people that we don't know how to help. And right now many of those people are finding their own way without us. I'm not asking anyone to lower the
140:33
Speaker A
bar for safety. But I'm asking us all to raise access to need it. Bill C286, known as Thomas's bill, would allow physicians to prescribe psilocybin directly and speed up Health Canada review, moving access out of a case-bycase exemption into regulated
140:50
Speaker A
medical care. I know people are seeking this care and the question is whether we will be there with them when they do. Thank you.
141:01
Speaker A
Thank you so much for your testimony both of you and the important work that you both do in your individual clinics.
141:08
Speaker A
Uh right now clinics like yourselves and across Canada are utilizing ketamine which is a psychedelic that is um um powerful and there is success with um that I've heard of from patients and from clinics similar to yours. Um,
141:25
Speaker A
talking about successes though, Ben, can you give me another example of a patient that um you were surprised with or the turnaround has been um different than what you expected?
141:42
Speaker A
I have I have many examples. Um it's it's hard to to think of just one. Um, but I can say that for some of the folks that we see, it doesn't have to be um an enormous change in their lives
142:01
Speaker A
for it to be meaningful. And for some, it's the ability to get out of bed in the morning without feeling the weight of the world on their shoulders or being able to go grocery shopping or to drive themselves to the grocery store because
142:14
Speaker A
they're no longer afraid to be behind the car or they don't squeeze the steering wheel every time they hear the sound of a siren. Um, and they can be around crowds again. And so those are the little steps that
142:28
Speaker A
sometimes people take to continue the work thereafter. Um but one of the the client that really led to me um taking the leap to opening flows therapy was when I was first kind of skeptical about the work we were doing and I wasn't sure if this
142:49
Speaker A
was if this was really working. I wasn't sure what we were doing here. coming from, you know, the emergency department. My background is a, you know, as a registered nurse and uh it it was someone uh who's a veteran who uh
143:01
Speaker A
struggled for many many years for over 15 years and nothing was helping and they felt far away from their kids and from their family. They didn't enjoy the activities that they usually enjoyed on a daily basis. Um and
143:17
Speaker A
for him he was unable to forgive himself from leaving a war torn country in which children were being affected every day.
143:26
Speaker A
And that guilt and shame stayed with him many years after he left until he was able to go through sessions of ketamine assist psychotherapy or psychedelic assisted therapy um at a clinic in which he found a way to forgive himself and to
143:44
Speaker A
relieve himself of the guilt and responsibility and to find love for those around him again. And I realized that we're not just helping that one individual, but then their kids get a dad back and their wives get a
143:58
Speaker A
husband back or wife back, their cousins and their friends and their communities. And so it's not just about the individual, it's about the communities around them as well.
144:08
Speaker A
Let's give more Canadians their lives back hopefully. Ben, thank you so much. Rev. Do you have a patient that comes to mind?
144:16
Speaker A
Um, yes. I I think all of us as clinicians have a a few that have touched our heart. Uh one specifically uh was actually a first responder who had gone through many many um I could say options for mental health treatment
144:33
Speaker A
not to have any success came and saw us at a clinic uh at the clinic and over a short time um two things occurred uh in their response in moving forward in their quality of life. The first is they
144:46
Speaker A
acknowledged they had never been seen and heard in such a way with a clinician and a health care team as to what we were able to do when we incorporated all of those interprofessionals or interdisciplinary professionals. So that
145:01
Speaker A
was the first thing they said. Like the type of care they received was amazing and it allowed them as they moved through their program with us to be able to really work on some of the areas that were holding them back. This individual
145:15
Speaker A
being a first responder was off on uh workers compensation here in Alberta and had not been able to return back over the course of the treatment. Um they came back and they actually had started back in their work part-time. So
145:30
Speaker A
contributing not only to their family but to the community and then really felt as though those gains when they sat with the medicine and our interdisciplinary team allowed them to explore other things in their life um that they were actually not even sure
145:46
Speaker A
that they were interested in. So they actually took up writing a book and have come back to the team a couple of times.
145:53
Speaker A
So first of all was back to work. second had experienced health care in the way that they hadn't for a long time. And the third uh took up um something that they didn't know they had in them and
146:04
Speaker A
are starting to write a book. That's fabulous. You're changing people's lives. And I I know that that you do that at the clinic um every day.
146:12
Speaker A
And um just in conclusion though, Rev um and Ben, how how would they find how do people find you Rev?
146:20
Speaker A
What website? What's the the best way here in Edmonton? And where are your clinics again and the network of clinics?
146:26
Speaker A
For sure. So, we have a clinic in Edmonton and Alberta and as I alluded to, they're um overseen by provincial licensing and college accredititation standards. And then we have a group of uh clinics across the country in Ontario, uh actually Saskatoon, uh
146:42
Speaker A
Winnipeg that are supporting um psychedelic assisted therapy through the approach and the protocol that we have taken in an accredited and licensed environment in Alberta. Um, if clients are looking for access to services, um, they can reach out to our website,
146:57
Speaker A
www.ncena.com and then there's a referral form for both their therapist or their clinician, which is their physician that they can use to send a request into us. If they're just looking for some information, uh, they can set up an
147:13
Speaker A
information call with us, and we do that all the time. Great. Thank you both of you guys so much for the work that you do with patients and thank you for being here today.
147:23
Speaker A
Thank you. Hey Rev. I'd like to call you off. [laughter] There she is. I'd like to call Jeremy Richard and Jason Nickerson up next, please.
148:01
Speaker A
Okay, Jeremy, I'll let you let you begin. Thanks. Okay. Hi everyone. Uh thank you Mr. Tucker and uh to all the speakers that have gone before me.
148:14
Speaker A
My name is Dr. Jeremy Richard and I'm an assistant professor uh and clinical psychologist at the school of psychology uh at the University of Ottawa where I direct the clinical and applied psychedelic uh science lab and teach within the psychedelics and
148:28
Speaker A
consciousness studies graduate program. I completed my doctorate at McGill University and uh my post-doal fellowship at Johns Hopkins School of Medicine. My research focuses on transdiagnostic treatments to mood disorders, anxiety disorders, post-traumatic stress disorder, and substance related and addictive
148:47
Speaker A
disorders. I'm here to speak about psilocybin, a naturally occurring psychedelic compound found in over 200 species of fungi, and about research Canada needs to do for psilocybin to become a supported therapeutic.
149:01
Speaker A
Most of our current psychiatric treatments are built around one diagnosis at a time. However, mental disorders are rarely present independently.
149:10
Speaker A
This is a concept known as psychiatric coorbidity. Mental disorders share underlying processes such as rigid patterns of thinking, avoidance, and difficulties regulating emotions. A transdiagnostic treatments uh targets these shared processes rather than emerging symptoms. Psilocybin assisted therapy is an emerging transdiagnostic
149:31
Speaker A
treatment. It features two elements. The first is pharmarmacology. Psilocybin acts on the brain in several ways, including by activating the serotonin 2a receptor. It also temporarily alters the brain's usual patterns of activity and appears to open a window of heightened neuroplasticity
149:49
Speaker A
that is noticeable behaviorally as a period of greater flexibility and in how people think, feel, and behave.
149:57
Speaker A
The second is psychotherapy. Preparation meetings, support during dosing, and intentional follow-up sessions help people use that window to make lasting change.
150:17
Speaker A
necessarily. In my professional opinion, answering these types of questions requires two types of research. One, rigorous clinical trials, some of which are already happening in Canada right now.
151:00
Speaker A
And two, monitored hybrid implementation outcome programs that test these treatments in real healthare systems.
151:15
Speaker A
First, end of life and serious illness care. Many Canadians living with cancer or other lifelimiting illnesses experience demoralization that current care does not adequately address. I currently co-chair the education and training committee of the Canadian network for psychedelic assisted cancer
151:33
Speaker A
therapy. In 2027, the network is launching our first large phase two trial of psilocybin for demoralization in cancer. And this will be followed within three years by a larger phase three trial. Togethers, these studies should be sufficient to
151:48
Speaker A
define the benefits, risks, and conditions of use for psilocybin in Canada. Second, post-traumatic stress disorder, particularly among veterans and public safety and public service personnel, but not only those populations.
152:02
Speaker A
The evidence that psilocybin uh that thats that psilocybin can work in PTSD is still very limited though. To my knowledge, only two large or moderately sized clinical studies have been published, both this year in 2026, involving a total of 34 participants. No
152:22
Speaker A
clinical research to date has focused on Canadian veterans or public safety personnel. I think this needs to change.
152:29
Speaker A
Third, addiction. This is a growing crisis in Canada across alcohol, tobacco, opioid, cocaine, and cannabis use disorder. We do have preliminary data suggesting both safety and efficacy of psilocybin therapy. This potential may also extend to behavioral addictions such as gambling disorder. Yet, once
152:47
Speaker A
again, very little of this research is happening here in Canada. Speaking of cost, I believe it's important to compare the efficacy of synthesized psilocybin with that of botanical mushrooms which contains psilocybin along with other compounds.
153:21
Speaker A
the the botanical option is likely to be more affordable, but we cannot assume that it's equivalent in efficacy to what we currently see in clinical research.
153:31
Speaker A
Despite the need for more research, it's also the case that many Canadians living with conditions where evidence is already encouraging cannot realistically access this type of care today. This is why I support giving physicians with the necessary training the authority to
153:45
Speaker A
prescribe psilocybin where the evidence supports it. This would improve access for people who have failed other available evidence-based treatments.
153:54
Speaker A
Access and evidence must move forward together. Prescribing, I believe, should come with the requirement for highquality documentation, namely how the treatment was delivered, what clinical outcomes are observed, and what adverse events were also observed.
154:09
Speaker A
This is where I believe monitored hybrid implementation outcome programs matter. Every prescription can then become a source of real world data. Done well, expanded access does not necessarily replace research. It actually strengthens it. Finally, this Canadian research on psilocybin will likely
154:28
Speaker A
require the investment of taxpayer money. I strongly support keeping this money working in Canada. And I'm not alone in this. It's consistent with triouncil policy where funded researchers are encouraged to prioritize can Canadian suppliers, services, and materials wherever possible.
154:45
Speaker A
Psilocybin assisted therapy offers a rare opportunity, a transdiagnostic treatment that targets shared mechanisms across psychiatric disorders.
155:18
Speaker A
Mercy. Thank you very much. Thank you. And then we'll hear from Jason Nickerson. Great. Thanks very much. I'm Dr. Jason Nickerson. I'm a respiratory therapist with background in adult acute care and anesthesia. I have a PhD in population
155:35
Speaker A
health. Um I'm appointed as an assistant professor of clinical public health at the University of Toronto. I'm an adjunct professor of common law at the University of Ottawa and an investigator at the Briair Health Research Institute here in Ottawa. Uh I'm also a
155:48
Speaker A
humanitarian aid worker. I spent 10 years working for Doctors Without Borders, uh, which alongside my clinical work has taught me firsthand about trauma and moral distress in the face of incredibly challenging and distressing experiences that can profoundly change
156:01
Speaker A
how people understand themselves and the world. Uh between 2014 and 2016, my work actually focused on access to controlled medicines within the international drug control treaties uh including defending global access to ketamine at the United Nations Commission on Narcotic Drugs uh
156:18
Speaker A
in particular for use in anesthetic care. But this was happening just as the evidence was emerging of ketamine's use and treatment resistant depression as well. My message at that time is actually the same as it is today. drug
156:31
Speaker A
policy must protect people from harm while ensuring that regulation itself does not become a barrier to care.
156:38
Speaker A
All of this uh happens to be within my professional wheelhouse of sorts. Uh but my most important perspective today uh is actually as a parent. I'm an adoptive parent to two kids uh who are now young adults and whose lives have been quite
156:54
Speaker A
profoundly affected by early childhood experiences and traumas um that have led to subsequent mental health uh difficulties. Their experiences are not my stories to tell and I'm I'm not going to get into into the details. Um I'm here simply as an expert and as a parent
157:10
Speaker A
who has witnessed their struggles and the limits of what our health system can offer. And I want to make two points.
157:17
Speaker A
The first is that we urgently need better treatments for trauma related disorders and adolescence must have a place in that research agenda alongside young adults.
157:27
Speaker A
Effective psychological treatments exist for trauma- related disorders, but they don't work for everyone. access is uneven. And talk therapy is particularly challenging for adolescence and young adults because it requires you to have the emotional voca vocabulary and readiness to be prepared to process
157:44
Speaker A
traumatic experiences which of course not everyone is ready for uh particularly early on in our lives. On medication, the evidence supporting medications that are commonly used for PTSD and other trauma related disorders in young people is particularly limited.
157:59
Speaker A
And I would also add that clinicians knowledge of treatment pathways for complex developmental trauma, particularly within the medical system, is unbelievably poor. Put simply, the treatment options are not good. The care pathways are often non-existent, and families can find themselves navigating
158:15
Speaker A
years of appointments, therapies, and off label prescriptions. While meaningful recovery remains elusive, we need to investigate approaches that might help people engage with traumatic experiences and distressing emotions that remain overwhelming or difficult to put into words.
158:30
Speaker A
In my opinion, psilocybin assisted therapy and psychedelic assisted therapy in general deserves rigorous investigation as one possible approach.
158:38
Speaker A
And to be clear, its promise is a reason to do the research. It's not a substitute for it.
158:46
Speaker A
And I would add that adolescence and young adults should not be categorically excluded from the possibility of benefiting from that research. That means a carefully staged research program that's informed by and occurring alongside adult evidence with specialist oversight, meaningful consent,
159:02
Speaker A
independent safeguards, and of course long-term follow-up. Now, obviously, developing brains require particular caution. Um, but I want to emphasize that so do lives being shaped by persistent and disabling traumatic experiences. We need to weigh the uncertainties of new treatments
159:18
Speaker A
alongside the consequences of continued distress and disability as well as the limitations of existing care, which I'll note is not benign when we consider the litany of pharmaceutical treatments that are often used in many cases off label to help young people manage. My second
159:34
Speaker A
point concerns how we actually regulate access. And I want to say that I unequivocally support regulation.
159:41
Speaker A
Psilocybin and other psychedelics are powerful substances that can produce frightening experiences and serious harms when they're used inappropriately.
159:48
Speaker A
But I don't believe that a physician or other clinician's prescription should be the only model that we're willing to consider for adult access. People also seek help with grief, moral distress, spiritual questions, and a profound sense of disconnection in our world.
160:02
Speaker A
These are real, at times distressing experiences, but they are not necessarily mental health disorders that require treatment. They can be part of the human experience.
160:11
Speaker A
For some, psychedelic experiences carry deeply personal, relational, or spiritual meaning. And a regulatory framework should be capable of recognizing those dimensions without assuming that every experience of value must be considered, must be carried out in a clinical setting. So what we need
160:26
Speaker A
is a distinct accountable framework uh that supports adult access beyond exclusively clinical settings while still requiring trained facilitators, safeguarding against exploitation and referrals to clinical care when needed.
160:40
Speaker A
So my request is similar to what we've heard throughout the day, which is that we need to support rigorous research um including a responsible pathway for adolescence and young adults who are struggling with mental health uh disorders. Well, we need to consider
160:54
Speaker A
regulation that's broad enough to accommodate different adult needs as well. We owe our families better options. We owe them honest evidence and a system that's willing to investigate possibilities with urgency and care.
161:06
Speaker A
Thanks. Thank you guys for the testimony today and more the the work that we do in research. It's it's um it's led by people. It's led by people like you two and others in this room. It's the research that will give the confidence
161:23
Speaker A
that that physician can prescribe psilocybin to their patient um with precautions and with appropriate research to support the use of those indications. That that's what's coming, but it comes from researchers like the two of you. We talked about um
161:38
Speaker A
observational or um hybrid um uh can you unpack that a little bit for the viewers at home? What would that study look like if we took a 100 patients um through um a trial with psilocybin? Uh what would
161:52
Speaker A
that be like? So a hybrid implementation outcome study takes the work we're doing in clinical trials with an eye on implementation science. What that means is really translating that research if it works into actual practice. For example, that's what we're doing at the Canadian
162:10
Speaker A
uh network for psychedelic assisted cancer therapy. We're running our clinical trials. We're designing those clinical trials with facilitators in hospitals in the actual health care system in Canada and if it works those systems will remain in place to provide
162:24
Speaker A
access after those trials are over. I think this can expand to various other programs. Um I know Gordon Hurley has talked about expanded access programs for veterans. This can be similar open the door to researching these access programs and measuring outcomes and how
162:40
Speaker A
these things are done. And so that way you actually open access at the same time as conducting the research. And if it works, stop the research, keep the access.
162:50
Speaker A
And Dr. Nickerson um talking about um uh how new medications um uh for adolescence hit the market. Um h how does that work with another product? Um because the the the epidemic of me mental health challenges with our
163:09
Speaker A
teenage population are massive obviously and and and there's challenges with the youth. Um the precautionary around prescribing med medicines to a minor is there for a reason. We know the research shows that psilocybin doesn't um um change the the development of the brain
163:27
Speaker A
in those early years. Um, so there's there's great uh hope that it's not going to be um a cautionary um indication for minors, but how would one approve a molecule for a minor?
163:42
Speaker A
Yeah. So um I'm not an expert in in drug regulatory pathways unfortunately but um you know I can say two things. Uh first of all you need a a similar standard of of clinical evidence that that um has
163:55
Speaker A
been collected in the population of interest, right? So you need to study this in you know a a a young adult adolescent population. That work is to some extent happening. There is an ethical discussion that is happening around how do we actually do this
164:10
Speaker A
recognizing of course what it is that you're you're you're describing here which is that you know this is a potent uh psychoactive substance and in being administered potentially in a developing brain. So, um, you you need properly designed and and
164:26
Speaker A
rigorously conducted and and monitored clinical trials. Some of those clinical trials are are happening. Um, there are two scoping reviews that I'm aware of that have have looked at clinical trials that are registered in clinical trials.gov. There's one published in
164:40
Speaker A
Lancet Psychiatry in 2025 that found three studies were registered. Um, there was a more recent one published uh in spring of this year. I believe they found 13 studies were were registered uh one with psilocybin, one with MDMA and
164:54
Speaker A
and the rest with either ketamine or esetamine. Um but you know fundamentally what this is about is generating uh evidence to to you know decide if this is safe and efficacious in in this population. And you know I think again
165:11
Speaker A
the the key message here is to remember that we're we're looking at risks and benefits. Everything in life has a series of risks and benefits. And I think that it's important to emphasize that the current treatment options that
165:23
Speaker A
are available are often off label prescriptions that, you know, are are not benign substances in and of themselves. That's not an anti-csychiatry kind of message. That's not what I'm promoting. Um, but, you know, we we need to be looking for
165:38
Speaker A
efficacious treatments that can be studied uh and rigorously evaluated. You've um everyone here probably has heard me ra a little bit about the need for more research in Canada on psilocybin. We are uh actively collecting petitions uh so that I could
165:55
Speaker A
uh get up and uh raise the point in the House of Commons um because we do need more research. We need catalyst funding in the hundreds of millions of dollars per annual in Canada if we are going to
166:08
Speaker A
meet the moment. The moment is in our streets outside this community uh room on the streets in Ottawa is a tent that I've walked by for six years now. I've met the individual that lives two blocks from our House of Commons that lives in
166:24
Speaker A
a tent. I'm not sure fully his challenges, but it's a pretty good indication I think for all MPs that work in Ottawa or when they wait we get to Ottawa that we see individuals that are suffering unfortunately and nothing has worked.
166:42
Speaker A
That is why that individual when we leave this committee room that's still living in that tent is because we have either not addressed the mental health challenges that he may have or the addictions of self-medicating that many in find themselves in similar situations
166:59
Speaker A
that that that do but is the research and the real world research because there's a component of research I think that gets done uh in the ivory towers and the universities that don't reflect what the population actually how they
167:11
Speaker A
utilize the medicine and be it on the preparation or integration side of things, we need more research to figure out the full potential of this plant.
167:22
Speaker A
And uh I if I do my job and if everyone else that's watching right now is doing theirs, contact your member of parliament regardless of political stripe and talk to them about psilocybin. It's not a political issue.
167:34
Speaker A
It's a healthcare issue and we'll have uh a vote here shortly on Thomas' bill that I I am very hopeful that will pass.
167:42
Speaker A
And it's because of everyone that is watching right now that has reached out to their elected officials to remind them to go vote in favor of Thomas' bill. But do for the people in uh in the room and that are watching that are in
167:55
Speaker A
the research side of things um I I'm big believer is that the way we get to a better spot in Canada with psilocybin regulation um is is partially through Thomas' bill, but it's it's through the work that you do. It's the research and
168:09
Speaker A
the science that shows that we are in the right path with psilocybin. So with that, thank you for uh being here today.
168:16
Speaker A
And Helen, who do we have up next? Uh virtually Karina Lanoski. I'm sorry. I'm trying to get my video to work, but it doesn't seem to be.
168:33
Speaker A
Take a pause. We got We got time. Okay. Okay, I cannot enable my video. Um, if the host could do that, you would be able to see me.
169:08
Speaker A
Oh, here we go. Great. Thank you. Good afternoon, everyone. My name is Karina Lenakosski and I'm the director of quality at Optim Health. I've worked in pharmaceuticals for my entire career, including decades in regulating new substances, drugs, and cannabis. And I'm
169:24
Speaker A
here to talk a little bit about the part of the conversation that usually gets skipped, which is where the legal medicine comes from and supply chain.
169:32
Speaker A
So, Optimi Health is a Health Canada licensed pharmaceutical manufacturer based in Princeton, British Columbia, where a small town about 3 hours east of Vancouver. Today, psilocybin capsules made in Princeton, BC, are being routinely prescribed to patients in Australia. But a Canadian patient who
169:49
Speaker A
wants that same capsule has to apply to Ottawa and wait for permission one patient at a time.
169:55
Speaker A
We make two products, capsules of naturally derived psilocybin extract and MDMA capsules. Both are made to the same pharmaceutical standards as any other prescription medicine you'd pick up in a pharmacy. We are regularly inspected by Health Canada's regulatory operations
170:10
Speaker A
and enforcement branch for GMP and the Office of Controlled Substances for our possession and production of controlled substances.
170:18
Speaker A
In 2023, Australia became one of the first countries in the world to allow psychiatrists to prescribe psilocybin under what's called the authorized prescriber scheme. This is a program for access to non-registered medicines for approved indications.
170:32
Speaker A
We at Optimize supply finished product capsules into that system and our products are being prescribed to Australian patients across through clinics across the country. I also just returned from a conference in the Czech Republic where access to psilocybin was
170:45
Speaker A
recently legislated and they're working through supply chain indications implications. Here at home, our products could be available through Health Canada's special access program. But I'll say the first time I received an SAP request for the indication of end of life distress,
171:02
Speaker A
an application that was ultimately accepted, the patient never made it to dosing. These stories are not uncommon in Canada because access is slow and often described as a black hole. As a manufacturer with medication that works and is routinely prescribed via
171:16
Speaker A
Australia's exceptional regulatory path, it is hard to see a lack of access in my own country.
171:22
Speaker A
I do want to spend a moment on three letters that don't usually come up in conversations about psychedelics, and that is GMP, which stands for good manufacturing practice. GMP is what turns a substance into a medicine. It means every capsule contains the same
171:36
Speaker A
dose as is on the label. At Optimi, we start with the whole mushroom. We grow it indoors in clean rooms under organic conditions. So we have complete control of the inputs and therefore complete control over the impurities. We extract,
171:51
Speaker A
formulate and put it into a capsule, test and release it. GMP means every batch is tested for purity and contaminates before it's released. It means we know how long the product stays stable because we test every batch over
172:02
Speaker A
the duration of its shelf life. It also means the facilities and processes that make our product have demonstrated control year-over-year. So when people ask whether Canada can produce or supply these medicines safely and reliably, we already do. However, a patient in Canada
172:18
Speaker A
today is more likely to find mushrooms in an online retail outlet than be able to access RGMP medication. A mushroom bought from such a storefront offers none of the controls you'd expect for a medication. Elicit products have widely
172:31
Speaker A
varying potency and microbial, heavy metal, and aphletoxin impurities that are unknown. And we know that this medication should be taken in conjunction with professional therapy, which is not likely to happen on the illicit market.
172:45
Speaker A
This is why I'd ask that as Thomas' bill moves forward, GMBB be part of the conversation from the start. The framework needs to specify pharmaceutical grade products, which are already enforced by Health Canada for regulated products. The bill proposes
172:59
Speaker A
priority review with decisions within certain number of days and that's a meaningful commitment and a vast improvement over today but it only works if manufacturers offer high-quality products and if Health Canada has resources to review the applications. So
173:13
Speaker A
my ask for today is first to work towards a real prescribing pathway not an exception process but a system that gives patients hope and access. Second that the pathway require pharmaceutical grade products made to Canadian GMP standards. so access and safety can move
173:29
Speaker A
forward together. And third, that Health Canada is resourced to make priority review work as intended.
173:36
Speaker A
I'd like to close with an anecdote from a clinic in Australia. This is a direct quote from a physician who used Optimize products.
173:45
Speaker A
A female who was presented with complex PTSD and severe PMDD which is premenstrual dysphoric disorder was facing chemicalinduced menopause or full hysterctomy surgery to reduce symptoms.
173:58
Speaker A
I advocated for her treatment team to hold back on both treatments while we did a psilocybin treatment protocol with her. After one dose she has no PMDDD symptoms anymore. We followed that session with an MDMA session and all
174:11
Speaker A
suicidal thoughts are gone. This patient is four months on and continuing to stabilize. I would like to hear more of these stories from Canadian patients.
174:20
Speaker A
And on behalf of the team at Optimi Health, thank you. Thank you so much uh for that. Um for the viewers at home that have just watched this. Um, Optima is a Canadian-owned Canadian operated Canadian mushrooms that they extract the
174:39
Speaker A
psilocybin and ship it all to Australia for the benefit of their health care system. And that's what's got to stop.
174:47
Speaker A
This is this is the if we're talking about sovereignty of our nation, uh, we have an example that that I I would hope I'm not proud of. I I would hope any elected official is not proud of that we
174:59
Speaker A
have a company that can operate and sell into Australia but not into Canada. And just like we've heard of other Canadian um psilocybin companies that are having difficulties obviously with the the with the regulatory and the um red tape. Um
175:16
Speaker A
that's why Thomas bill has to pass. It's it's for the examples such as for optimi optimize or the red light or um all the other um uh blue stem and other companies out there that are Canadian that that we want our country to
175:31
Speaker A
succeed. Companies like this should be the ones that we should be holding up as examples um to be emulated in other industries. Um I guess for the question to op optimize though is um the you talked about the example in
175:49
Speaker A
Australia. Um what are other countries that you guys will probably get into? As much as we're very hopeful that Thomas' bill is going to pass in the next few months, I I I suspect you could you could be selling into other countries
176:01
Speaker A
here sooner. What's the international plan? It's very much country by country at this point in time. At that conference that I attended in Prague, uh all the countries came to Prague because they wanted to hear about how Czech regulated
176:15
Speaker A
and how they opened up access. Uh I do believe over the next few years a lot of European countries especially will open up some kind of compassionate use program so that people can gain access.
176:25
Speaker A
There is a very special focus on veteran accessibility. At this point in time, all other sales are clinical trials. So we do have clinical trials internationally. But in terms of the um special regulatory pathways for prescription so far it's it's Australia
176:41
Speaker A
and um and check putting theirs into place and we've asked others psilocybin uh companies that presented today about a little bit on their their pricing that might be in in Canada and I know that uh you may not not have as a company
176:57
Speaker A
settled on what that price might be but are you uh below compasses 25,000 US I'm assuming?
177:03
Speaker A
Yes. [snorts] under 10,000 for the medicine probably. Um probably yes. I don't have exact pricing and pricing obviously always depends on volumes. Uh right now this is a small volume business.
177:15
Speaker A
Yeah. I I'm concerned where we're we may in Canada have access to a synthetic that is cost going to cost us thousands and thousands of dollars out of the reach of um um regular normal Canadians.
177:28
Speaker A
even wealthy Canadians might um be a little bit sticker shocked. And I I I believe that we have to bring another molecule to market hopefully such as optimize um a product where we I I do share the importance of GMP and being
177:46
Speaker A
able to be uh uh standardized that give them confidence. Is there anything else you'd like to share with the people that have tuned in to the summit?
177:56
Speaker A
No, nothing additional from my front. Thank you for having me today. All right. Well, thank you again for your testimony and for your answers. Um I'll have a little bit of closing remarks here, guys, and then we'll we'll
178:07
Speaker A
uh wrap up for the day. So, thank you everyone for being here today. Uh it's an honor to host the first of the annual uh psilocybin summit in our nation's capital. I'm very grateful for the some of the the workers that uh uh
178:25
Speaker A
came in on this week to make this all possible. And for all our witnesses and attendees, thank you so much. It is uh I am more sure today now than I have ever been that Thomas' bill has to pass and
178:41
Speaker A
it will pass because the testimony will be heard today. The science is there. We know that psilocybin is safe. Um it is a non-toxic molecule that you can't get addicted to. We have hundreds of of years of experience in um our indigenous
179:00
Speaker A
friends culture that have utilized this plant medicine for the the benefit. We have current studies that have shown that this is a safe and effective way to treat mental health and addiction. We need the regulations in Canada to match
179:17
Speaker A
up with the crisis that we have. And on the opportunity side for psilocybin sovereignty, we need a Canadian molecule that is Canadianowned, Canadian produced for our patients, for our sovereignty instead of relying on international partners that may be there or may not be
179:36
Speaker A
in the future. So, um, in conclusion, thank you everyone that has tuned in and has provided, uh, their testimony. I am so grateful for everyone's support, uh, of Thomas's bill. Thomas is, uh, looking down from above, smiling at what we
179:51
Speaker A
heard today, and I would hope, very proud of what was about to happen to the great nation of Canada with Sil Simon.
179:58
Speaker A
All the best. Thank you. [applause] [music] [music]
Topics:psilocybinpsychedelic therapyveterans mental healthPTSDCanada drug policySection 56 exemptionneuroplasticitymental health accessparliamentary testimonyregulated access

Get More with the SozAI App

Transcribe recordings, audio files, and YouTube videos — with AI summaries and speaker detection. 30 minutes free.

Or transcribe another YouTube video here →